Interferon gene stimulatory composition containing an indolizine derivative as an active ingredient

The indolizine derivative and cyclic di-nucleotide composition synergistically activates the cGAS-STING pathway, addressing limitations of ICIs by enhancing immune response in cold tumors and improving cancer treatment efficacy.

JP7590565B2Active Publication Date: 2024-11-26AJOU UNIV IND ACADEMIC COOP FOUND +1
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023525004
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-10-23
Filing Date
2021-10-22
Publication Date
2024-11-26
Estimated Expiration
2041-10-22

AI Technical Summary

Technical Problem

Current immune checkpoint inhibitors (ICIs) for cancer treatment have limitations such as efficacy in only some patients and cancers, and resistance can develop, necessitating new methods to activate the cGAS-STING pathway for enhanced immune response in cold tumors.

Method used

An interferon gene stimulator composition containing an indolizine derivative and a cyclic di-nucleotide, which synergistically activates the cGAS-STING pathway, enhancing immune response even at low concentrations.

Benefits of technology

The composition achieves high activity in activating the STING pathway with reduced cyclic di-nucleotide concentration, improving immune response and potentially increasing the effectiveness of cancer treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007590565000167
    Figure 0007590565000167
  • Figure 0007590565000168
    Figure 0007590565000168
  • Figure 0007590565000169
    Figure 0007590565000169
Patent Text Reader

Abstract

The present invention relates to an interferon gene stimulating agent composition containing an indolizine derivative as an active ingredient, which can solve the problem of low disease control rate compared to the use of cyclic-dinucleotide alone, and more specifically, by using it together with the compound of Chemical Formula 1, it can have high activity even with a low concentration of cyclic-dinucleotide.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This specification claims the benefit of the filing date of Korean Patent Application No. 10-2020-0138399, filed with the Korean Intellectual Property Office on October 23, 2020, the entire contents of which are incorporated herein by reference. The present invention relates to an interferon gene stimulating composition containing an indolizine derivative as an active ingredient. [Background technology]

[0002] Recently, the field of cancer treatment is undergoing a paradigm shift from anti-cancer chemotherapy and targeted anti-cancer drugs that attack cancer itself to immune anti-cancer drugs that activate the body's immune system to attack cancer. Among them, immune checkpoint inhibitors (ICIs) have been attracting attention for their excellent and sustained clinical efficacy. However, there are still limitations, such as the efficacy of the same therapeutic agent only in some patients or cancers and the development of resistance. As a result, active research is being conducted on tumor microenvironment (TME) factors that affect the efficacy of immune anti-cancer drugs and the immune evasion mechanisms of cancer.

[0003] The degree of immune cell penetration into tumor tissue is a crucial factor in the success of immunotherapy. Cold tumors have a defect in the early stages of the cancer-immune cycle, and are largely unresponsive to ICIs. During tumor formation, the cancer immune surveillance system removes cancer cell clones expressing highly immunogenic neoantigens. Tumors avoid anti-cancer immune responses by removing immunogenic antigens or by maintaining cancer cell clones lacking cancer antigens so that they are not recognized by T cells. In other words, cancer cell clones that have escaped the immune surveillance system have fewer immunogenic antigens. Therefore, there is an emerging need for innate immune inducers that increase immune reactivity around cancer cells.

[0004] Pattern recognition receptors (PRRs) are several different types of receptors expressed primarily by innate immune cells that can recognize specific PAMPs or DAMPs depending on their ligand specificity. Cytoplasmic DNA is a type of molecular pattern that is recognized by cytoplasmic DNA sensors (a type of PRR) to trigger innate immune responses. The cGAS-STING pathway (cGAS, cyclic GMP-AMP synthase; STING, stimulator of interferon genes) is involved in 1) the recognition of cytoplasmic DNA resulting from microbial infection or damage to the cell's own DNA, and 2) the generation of chemical factors, primarily type 1 interferons (IFNs), through activation of the IRE3 transcription factor.

[0005] Systemic administration of type 1 IFN has demonstrated efficacy in the cancer setting, with tumor regression and improved survival rates following systemic injection of IFN-beta in preclinical mouse models. However, systemic administration of type 1 IFN has the problem of requiring high doses to reach a therapeutically effective dose for therapeutic efficacy. In this case, drug tolerance issues have been reported.

[0006] A recently published report published clinical results of exogenous STING agonists (modified cyclic dinucleotides) showed lower than expected disease control rates despite a clear increase in pro-inflammatory cytokine production.

[0007] Therefore, there is a need for research into new therapeutic approaches that can activate the cGAS-STING pathway. [Prior art documents] [Patent documents]

[0008] [Patent Document 1] KR10-2018-0066241A1 Summary of the Invention [Problem to be solved by the invention]

[0009] One aspect of the present invention provides an interferon gene stimulatory composition comprising an indolizine derivative as an active ingredient. [Means for solving the problem]

[0010] One aspect of the present invention provides an interferon gene stimulatory composition comprising an indolizine derivative compound represented by the following formula 1: and a cyclic-di-nucleotide: [ka] In the above Chemical Formula 1, R1 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a halogen group; a nitrile group; a hydroxy group; a C1-C6 alkoxy group; -COY1 (wherein Y1 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 -CO2Y2 (wherein Y2 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY3Y4, where Y3 and Y4 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R2 is [ka] or a pyridinyl group, R4 and R5 are each independently hydrogen; a C1-C8 straight or branched chain alkyl group; a C1-C8 straight or branched chain alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; a C1-C6 alkoxy group; -COY5 (wherein Y5 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 -CO2Y6 (wherein Y6 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R3 is a C1-C8 straight or branched chain alkyl group; or [ka] and R6 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxy group; a C1-C6 alkoxy group; -COY9 (wherein Y9 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C20 aryl group);-CO2Y 10 (where Y 10 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 an aryl group; or -NY 11 Y 12 (where Y 11 and Y 12 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 Heteroaryl groups of the formula: Effect of the Invention

[0011] The composition of the present invention contains an indolizine derivative represented by Chemical Formula 1 and a cyclic dinucleotide, thereby solving the problem of a lower disease control rate compared to the use of a cyclic dinucleotide alone. Specifically, by using it together with the compound of Chemical Formula 1, it is possible to achieve high activity even with a low concentration of a cyclic dinucleotide. [Brief description of the drawings]

[0012] [Figure 1] This shows the results of an ISRE reporter assay to confirm the synergistic effect of compound 42 of the present invention by combined treatment with cGAMP, and to confirm STING dependency and concentration dependency. [Diagram 2] 1 shows the results of confirming the cytotoxicity caused by the combined administration of Compound 42 of the present invention and cGAMP. [Diagram 3] This shows the results of confirming the increase in expression of IFNb and IP-10 cytokines by combined treatment of compound 42 of the present invention with cGAMP (confirming the activation of STING (STIMULATOR OF INTERFERON GENE)-dependent signal transduction). [Figure 4]The results confirm that the combined administration of the compound of the present invention and cGAMP increases the expression of various Type I IFN signaling-related genes. [Diagram 5] The results confirm activation of STING (STIMULATOR OF INTERFERON GENE)-dependent signal transduction by combined treatment of the compound of the present invention with cGAMP. [Figure 6] This is a result of comparing the activation effect of STING (STIMULATOR OF INTERFERON GENE)-dependent signal transduction by combined treatment with a compound (MV658) known as a STING pathway treatment and the compound of the present invention and cGAMP. [Figure 7] This shows the results of confirming the in vivo anticancer activity effect of compound 42 of the present invention in combination with cGAMP. [Figure 8] 1 shows the results of confirming the blood concentration profile over time after intravenous injection (IV) and oral administration (PO) of Compound 42 of the present invention. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0013] One aspect of the present invention provides an interferon gene stimulatory composition comprising an indolizine derivative compound represented by the following formula 1: and a cyclic-di-nucleotide: [ka] In the above Chemical Formula 1, R1 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a halogen group; a nitrile group; a hydroxy group; a C1-C6 alkoxy group; -COY1 (wherein Y1 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20-CO2Y2 (wherein Y2 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY3Y4, where Y3 and Y4 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R2 is [ka] or a pyridinyl group, R4 and R5 are each independently hydrogen; a C1-C8 straight or branched chain alkyl group; a C1-C8 straight or branched chain alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; a C1-C6 alkoxy group; -COY5 (wherein Y5 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 -CO2Y6 (wherein Y6 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R3 is a C1-C8 straight or branched chain alkyl group; or [ka] and R6 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxy group; a C1-C6 alkoxy group; -COY9 (wherein Y9 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 aryl group);-CO2Y 10 (where Y 10 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 an aryl group; or -NY 11 Y 12 (where Y 11 and Y 12 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 Heteroaryl groups of the formula: Specifically, in the above Chemical Formula 1, R1 is hydrogen; a C1-C8 linear or branched alkyl group; a C1-C8 linear or branched alkyl group substituted with a halogen; or -COY1 (wherein Y1 is hydrogen, a C1-C8 linear or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C8 cycloalkyl group). 20 In this case, Y1 may be, more specifically, a C1-C8 linear or branched alkyl group. In addition, in the above-mentioned chemical formula 1, R2 is [ka] R4 and R5 are each independently hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with a halogen; a C1-C6 alkoxy group; a carboxyl group; -COY5 (wherein Y5 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 In this case, Y5 may be, more specifically, a C1-C8 linear or branched alkyl group, and Y7 and Y8 are each independently hydrogen or a C1-C 10 The alkyl group may be any of the groups represented by the formula: In addition, in the above formula 1, R3 may be a C1-C8 linear or branched alkyl group, specifically, a methyl group. [ka] where R6 is hydrogen, a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with a halogen; a C1-C6 alkoxy group; or -NY 11 Y 12 (where Y 11 and Y 12 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 In this case, Y is a heteroaryl group. 11 and Y 12 are each independently hydrogen or C1-C 10 The alkyl group may be any of the groups represented by the formula: The indolizine derivative compound represented by Chemical Formula 1 may be any one of the compounds represented by Chemical Formulas 1a to 1c below. [ka] [ka] [ka]

[0014] In the above Chemical Formulae 1a to 1c, the definitions of R1, R3, R4, R5, and R6 are the same as those of R1, R3, R4, R5, and R6 in the above Chemical Formula 1.

[0015] The indolizine derivative compound represented by Chemical Formula 1 can be prepared according to the following Reaction Scheme 1. [ka]

[0016] Specifically, the method for producing the indolizine derivative compound represented by the above-mentioned Chemical Formula 1 includes the steps of: (a) reacting a compound of formula A and a compound of formula B to produce a compound of formula C; (b) reacting the compound of formula C with ethyl acrylate, sodium acetate and copper(II) acetate monohydrate to prepare a compound of formula D; (c) reacting the compound of formula D with N-Bromosuccinimide (NBS) to prepare a compound of formula E; (d) reacting the compound of formula E with the compound of formula F to produce an indolizine derivative compound represented by formula 1.

[0017] The specific details regarding the preparation method of the indolizine derivative compound represented by Chemical Formula 1 are as follows.

[0018] Step (a): Acylation of pyridine substrate In this step, the compound represented by formula B is acylated using an alkyl halide.

[0019] The acylation can be carried out using a conventional method known in the art without limitation, but preferably, the alkyl halide represented by chemical formula B contains an electrophilic moiety such as 2-bromo-1-[4-(trifluoromethyl)-phenyl]ethane-1-one, chloroacetone, 2-bromoacetophenone, 2-bromo-4-methoxyacetophenone, 2-bromo-4'-(diethylamino)aceto-phenone, etc., containing an R3 substituent, and pyridine having an R1 substituent is used.

[0020] Specifically, an organic mixture solution of an alkyl halide and pyridine is stirred for 1 to 24 hours at an appropriate temperature (20° C. to 100° C.) to produce a pyridine salt compound. In this case, the organic solvent used in carrying out the reaction can be a common organic solvent, and can be appropriately determined by a person skilled in the art depending on the specific types of the alkyl halide and pyridine compound.

[0021] Step (b): 1,3-dipolar cyclization reaction In this step, the acylated compound represented by chemical formula C obtained in step (a) is reacted with ethyl acrylate, sodium acetate, and copper(II) acetate monohydrate to obtain a compound represented by chemical formula D.

[0022] Specifically, the organic mixture solution of the acylated compound obtained in step (a) is stirred at an appropriate temperature (50°C to 120°C) for 1 to 24 hours, and then undergoes normal extraction, drying, filtration, concentration and purification processes to produce a compound represented by chemical formula D. In this case, the organic solvent used in carrying out the reaction can be a normal organic solvent, and can be appropriately determined by a person skilled in the art depending on the specific type of compound.

[0023] Step (c): Br substituent introduction step This is the step of obtaining a compound represented by chemical formula E from a compound represented by chemical formula D through saponification and bromination reactions.

[0024] The reaction is carried out without limitation using a conventional method known in the art, but preferably, the compound represented by the formula D is first dissolved in an organic solvent, and a strong base such as lithium hydroxide, potassium hydroxide, or sodium hydroxide is added, and the resulting organic mixture solution is stirred at an appropriate temperature (50°C to 120°C) for 1 to 24 hours, and then undergoes conventional extraction, drying, filtration, concentration, and purification processes to obtain an intermediate. Thereafter, the intermediate is dissolved in a suitable organic solvent, and then NBS (N-Bromosuccinimide) is treated, and the resulting organic mixture solution is stirred at an appropriate temperature (50°C to 120°C) for 1 to 24 hours, and then undergoes conventional extraction, drying, filtration, concentration, and purification processes to obtain a compound represented by the formula E. At this time, the organic solvent used in the reaction can be a conventional organic solvent, and can be appropriately determined by a person skilled in the art according to the specific type of compound.

[0025] (d) Step: Suzuki coupling step In this step, the compound represented by the chemical formula E is reacted with the compound represented by the chemical formula F using a Pd catalyst to obtain the indolizine derivative compound represented by the chemical formula 1 of the present invention.

[0026] The reaction is carried out without limitation using a conventional method known in the art. First, the compound represented by chemical formula F containing the R2 substituent is not particularly limited, and preferably, trifluorophenylboronic acid, 4-acetylphenylboronic acid, phenylboronic acid, 4-methoxyphenylboronic acid, and 4-(dimethylamino)phenylboronic acid can be used. The reaction is carried out by mixing the compound represented by chemical formula F having the R2 substituent and the compound represented by chemical formula E obtained in step (c) with Pd(PPh3)4 and sodium carbonate in a conventional organic solvent, and stirring the resulting organic mixture solution at an appropriate temperature (50°C to 120°C) for 1 to 24 hours, followed by conventional extraction, drying, filtration, concentration, and purification processes to obtain the compound for aggregation-induced luminescence of the present invention. In this case, the organic solvent used in carrying out the reaction can be a common organic solvent, and can be appropriately selected by those skilled in the art depending on the specific type of compound.

[0027] The stimulator of interferon genes (STING) of the present invention is a receptor that recognizes nucleic acids different from TLRs (toll-like receptors). Examples of natural ligands that it recognizes include bacteria / protozoa-derived cyclic dinucleotides (CDNs), 2',3'-cGAMP synthesized by upstream cGAS (cyclic GMP-AMP synthase), etc. (Trends in Immunology 35:88-93 (2014)). One of the natural ligands, 2',3'-cGAMP, is degraded by ENPP1 (ecto-nucleotide-pyrophosphatase / phosphodiesterase), a type of pyrophosphatase / phosphodiesterase, and other CDNs have been reported to be degraded by phosphodiesterases (Nat Chem Biol 10:1043-1048 (2014); Cell Res 25:539-550 (2015); Biochemistry 55:837-849 (2016)). STING is activated by these natural ligands, and induces phosphorylation of TBK1 (TANK binding kinase 1) downstream, and further activates IRF3 (Interferon regulatory factor 3) signaling and NFkB signaling downstream, thereby inducing type I interferon (IFN) response (Trends in Immunology 35: 88-93 (2014)). The importance of STING signaling in cancer has been demonstrated by studies using knockout mice. It has been reported that cancer cells grow in allogeneic tumor-inoculated mice using knockout mice for STING and its downstream signal IRF3, due to suppression of the cancer immune system, compared to wild-type mice (Immunity 41: 830-842 (2014)).In addition, it has been reported that cancer cell growth in allogeneic tumor-implanted mice is suppressed by radiation therapy, but the effect of radiation therapy is reduced in STING and IFNAR1 (interferon (alpha and beta) receptor 1, a receptor for type I IFN produced by downstream signaling) knockout mice (Immunity 41: 843-852 (2014)). For these reasons, STING plays an important role in suppressing cancer cell growth, and activation of immune signals induced by STING activation is linked to anti-cancer activity. Therefore, STING agonists may be used as anti-cancer agents targeting cancer immunity. In addition, activation of STING is said to play an important role in the immune effect of vaccines, since its activation activates natural immunity (Ther Adv Vaccines 1: 131-143 (2013)). Therefore, STING agonists may be used as adjuvants for various vaccines.

[0028] The indolizine derivative compound represented by Chemical Formula 1 may be a compound represented by the following Chemical Formula 1-1 or a compound represented by the following Chemical Formula 1-2: [ka] [ka]

[0029] In the above chemical formula: R1 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a halogen group; a nitrile group; a hydroxy group; a C1-C6 alkoxy group; -COY1 (wherein Y1 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20-CO2Y2 (wherein Y2 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY3Y4, where Y3 and Y4 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R4 and R5 are each independently hydrogen; a C1-C8 straight or branched chain alkyl group; a C1-C8 straight or branched chain alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; a C1-C6 alkoxy group; -COY5 (wherein Y5 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 -CO2Y6 (wherein Y6 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R6 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxy group; a C1-C6 alkoxy group; -COY9 (wherein Y9 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 aryl group);-CO2Y 10 (where Y 10 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 an aryl group; or -NY 11 Y 12 (where Y 11 and Y 12 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 Heteroaryl groups of the formula:

[0030] Specifically, in the above Chemical Formula 1-1, R1 is hydrogen; a C1-C8 linear or branched alkyl group; a C1-C8 linear or branched alkyl group substituted with a halogen; or -COY1 (wherein Y1 is hydrogen, a C1-C8 linear or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C8 cycloalkyl group). 20 In this case, Y1 may be, more specifically, a C1-C8 linear or branched alkyl group.

[0031] In addition, in the above Chemical Formula 1-1, R4 and R5 are each independently hydrogen; a C1-C8 linear or branched alkyl group; a C1-C8 linear or branched alkyl group substituted with a halogen; a C1-C6 alkoxy group; a carboxyl group; -COY5 (wherein Y5 is hydrogen, a C1-C8 linear or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 In this case, Y5 may be, more specifically, a C1-C8 linear or branched alkyl group, and Y7 and Y8 are each independently hydrogen or a C1-C 10 The alkyl group may be any of the groups represented by the formula:

[0032] In addition, in the above Chemical Formula 1-1 and Chemical Formula 1-2, R6 is hydrogen, a C1-C8 linear or branched alkyl group; a C1-C8 linear or branched alkyl group substituted with a halogen; a C1-C6 alkoxy group; or -NY 11 Y 12 (where Y 11 and Y 12 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 In this case, Y is a heteroaryl group. 11 and Y 12 are each independently hydrogen or C1-C 10 The alkyl group may be any of the groups represented by the formula:

[0033] The compound represented by the formula 1a may include a compound represented by the formula 1-1, and the compound represented by the formula 1b may include a compound represented by the formula 1-2. The indolizine derivative compound represented by the formula 1 may be a compound represented by the following formula 1-3: [ka]

[0034] In the above chemical formula: R1 is hydrogen; a C1-C8 straight or branched alkyl group; a C1-C8 straight or branched alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a halogen group; a nitrile group; a hydroxy group; a C1-C6 alkoxy group; -COY1 (wherein Y1 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 -CO2Y2 (wherein Y2 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY3Y4, where Y3 and Y4 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 a heteroaryl group of the formula R4 and R5 are each independently hydrogen; a C1-C8 straight or branched chain alkyl group; a C1-C8 straight or branched chain alkyl group substituted with halogen; a C2-C8 alkenyl group; a C2-C8 alkynyl group; a C3-C8 cycloalkyl group; a C5-C 20 Heterocycloalkyl groups; C6-C 20 Aryl groups; C6-C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; a C1-C6 alkoxy group; -COY5 (wherein Y5 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 -CO2Y6 (wherein Y6 is hydrogen, a C1-C8 straight or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20or C4-C 20 (heteroaryl group), and R3 is a C1-C8 straight or branched chain alkyl group.

[0035] Specifically, in the above Chemical Formula 1-3, R1 is hydrogen; a C1-C8 linear or branched alkyl group; a C1-C8 linear or branched alkyl group substituted with a halogen; or -COY1 (wherein Y1 is hydrogen, a C1-C8 linear or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C8 cycloalkyl group). 20 In this case, Y1 may be, more specifically, a C1-C8 linear or branched alkyl group.

[0036] In addition, in the above formula 1-3, R3 may be a C1-C8 linear or branched alkyl group, specifically, a methyl group.

[0037] Further, in the above Chemical Formula 1-3, R4 and R5 are each independently hydrogen; a C1-C8 linear or branched alkyl group; a C1-C8 linear or branched alkyl group substituted with a halogen; a C1-C6 alkoxy group; -COY5 (wherein Y5 is hydrogen, a C1-C8 linear or branched alkyl group, a C2-C8 alkenyl group, a C2-C8 alkynyl group, a C3-C8 cycloalkyl group, or a C6-C 20 or -NY7Y8, where Y7 and Y8 are each independently hydrogen, C1-C 10 Alkyl groups, C6-C 20 or C4-C 20 In this case, Y5 may be, more specifically, a C1-C8 linear or branched alkyl group, and Y7 and Y8 are each independently hydrogen or a C1-C 10 The alkyl group may be any of the groups represented by the formula:

[0038] The compound represented by the above chemical formula 1c can include the compound represented by the above chemical formula 1-3. The indolizine derivative compound represented by the above chemical formula 1 may be any one of the following compounds 1 to 72. [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] [ka] Specifically, the compound represented by the chemical formula 1-1 may be any one of the compounds 1 to 60, 62 to 66, and 68 to 72. The compound represented by the chemical formula 1-2 may be the compound 61 or 67. The indolizine derivative compound represented by Chemical Formula 1 may be any one of Compounds 73 to 87 below. [ka] [ka] [ka]

[0039] Specifically, the compound represented by the above chemical formula 1-3 may be any one of the above compounds 73 to 87.

[0040] Cyclic dinucleotides (CDNs), the natural activators of STING mentioned above, are second messenger signaling molecules produced by various bacteria, consisting of two ribonucleotides linked by a phosphodiester bond to form a ring structure. CDN cyclo-di(GMP), cyclo-di(AMP) and hybrid cyclo-(AMP / GMP) derivatives all bind to STING with subsequent activation of the interferon pathway (Gao et al., Cell, 2013, 153, 1094-1107; Zhang et al., Mol. Cell, 2013, 51, 226-235). The formal 5'-3' phosphodiester bond is recognized along with a variety of other linkage isomers (notably the 5'-2' linkage, e.g., c[G(2',5')pA(3',5')p]), all of which bind to STING with varying affinities (Shi et al., PNAS, 2015, 112, 1947-8952). These observations were corroborated by structural studies of the various linkage isomers of CDN bound to human and mouse STING proteins (Gao et al., Cell, 2013, 154, 748-762).

[0041] One example of such a cyclic-di-nucleotide, cGAMP, is a heterodimer linked by one 3'-5' phosphodiester and one 2'-5' phosphodiester (2',3'-cGAMP), whereas bacterial CDN is linked via two 3'-5' phosphodiester linkages (3',3'-CDN), which can contain two guanosines, two adenosines, or one of each (Davies, BW, 2012). The affinity of 2',3'-cGAMP for human STING is very high, with a dissociation constant of 4.59 nM, compared to the dissociation constant for bacterial 3',3'-CDN of over 1 μM (Zhang, X. et al., 2013; Ablasser, A. et al., 2013; Diner et al., 2013).

[0042] However, native CDNs are sensitive to cleavage by phosphodiesterases present in host cells or the systemic circulation (Yan et al., 2008). To improve hydrolytic stability, we developed synthetic CDN compounds by replacing the non-bridging oxygen atom in the phosphate bridge with a sulfur atom. We found that the non-phosphothionate analog of endogenous cGAMP (ML cGAMP) was resistant to hydrolysis by ENPP1 phosphodiesterase; therefore, it was more potent in inducing IFN-β secretion in human THP-1 cells (Li et al., 2014). Similarly, R,R-dithio-modified cyclic di-AMPs (CDAs) (ML RR-S2 CDA and RR-S2 CDA) showed increased type I IFN production over CDA (Leticia C., et al., 2015). Intratumoral injection of ML RR-S2 CDA into B16 melanoma tumors also resulted in complete tumor elimination in the majority of ML RR-S2 CDA-treated mice and induced sustained systemic antigen-specific CD8+ T-cell immunity. Additionally, this was fully protective against a second tumor rechallenge. Similar results were observed in 4T-1 breast and MC26 colon cancer models.

[0043] Such cyclic dinucleotides have the problem of low disease control rate despite increased production of pro-inflammatory cytokines. The present invention has confirmed that by using cyclic dinucleotides having such problems together with the compound of Chemical Formula 1, high activity can be achieved even with the use of low concentrations of cyclic dinucleotides.

[0044] In one embodiment of the present invention, the cyclic-di-nucleotide may be substituted with fluoro at any one or more of the 2' and 3' positions. More specifically, the cyclic-di-nucleotide may be any one of the following compounds: [ka] [ka] [ka] [ka] [ka]

[0045] The compound 2-1 is 2,3-cGAMP, which is represented by adenylyl-(3'→5')-2'-guanylic acid, cyclic nucleotide (CAS Number 1441190-66-4), the compound 2-2 is 3,3-cGAMP, which is represented by adenylyl-(3'→5')-3'-guanylic acid, cyclic nucleotide (3,3-cGAMP adenylyl-(3'→5')-3'-guanylic acid, cyclic nucleotide) (CAS Number 849214-0), the compound 2-3 is c-di-AMP, which is represented by adenylyl-(3'→5')-3'-adenylic acid, cyclic nucleotide (adenylyl-(3'→5')-3'-adenylic acid, cyclic nucleotide) (CAS Compound 2-4 is c-di-GMP, which is a substance represented by guanylyl-(3'→5')-3'-guanylic acid, cyclic nucleotide (CAS Number 61093-23-0), and compound 2-5 is compound 27 disclosed in WO2017093933, which is (1R,6R,8R,9R,10R,15R,17R,18R)-17-(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-8-(6-amino-9H-purin-9-yl)-9-fluoro-18-hydroxy-3,12-disulfanyl-2,4,7,11,13,16-hexaoxa-3λ. 5 ,12λ 5 -Diphosphatricyclo[13.2.1.0 6 , 10]Octadecane-3,12-dione ((1R.6R.8R.9R.10R.15R.17R.18R)-17-(2-amino-6-oxo-6.9-dihydro-1H-purin-9-yl)-8-(6-amino-9H-purin-9-yl)-9-fluoro-18-hydroxy-3,12-disulfanyl-2,4,7,11,13,16-hexaoxa-3λ 5 ,12λ 5 -diphosphatricyclo[13.2.1.0 6 , 10 ]octadecane-3,12-dione]), compound 2-6 is compound CL614 disclosed in US20160362441 and is a substance represented by c-(2FdAMP-2FdIMP), and compound 2-7 is compound 76 disclosed in WO2017123669 and is [(1S,6S,8R,9R,10S,15S,17R,18R)-8,17-bis(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-9,18-dihydroxy-3,12-dioxo-12-sulfanidyl-4,7,13,16-tetraoxa-2,11-diaza-3λ 5 ,12λ 5 -Diphosphatricyclo[13.3.0.0 6,10 ]octadecan-3-yl]sulfanide ([(1S,6S,8R,9R,10S,15S,17R,18R)-8,17-bis(2-amino-6-oxo-6,9-dihydro-1H-purin-9-yl)-9,18-dihydroxy-3,12-dioxo-12-sulfanidyl-4,7,13,16-tetraoxa-2,11-diaza-3λ 5 ,12λ 5 -diphosphatricyclo[13.3.0.0 6,10Compound 2-8 is a compound 191 disclosed in WO2017027646, which is represented by the formula: 2-amino-9-[(5S,7R,8R,12aR,14R,15S,15aR)-14-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-15-fluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5,8-methanofuro[3,2-1][1,3,9,1,,6,2,0]tetraoxathiaziophosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one (2-amino-9-[(5S ,7R,8R,12aR,14R,15S,15aR)-14-(7-amino-3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-15-fluoro-2,10-dihydroxy-2,10-disulfidooctahydro-12H-5,8-methanofuro[3,2-1][1,3,9,1,,6,2,0]tetraoxathiadiophosphacyclotetradecin-7-yl]-1,9-dihydro-6H-purin-6-one), and compound 2-9 is the compound ADU-S100 commercially available from Aduro and is a substance represented by MIW815 (CAS Number 1638750-95-4).

[0046] Specifically, the compound may be a cyclic di-nucleotide, 2,3-cGAMP.

[0047] In one embodiment of the present invention, the composition may be for preventing or treating any one of autoimmune diseases, including cancer, solid cancer, non-T cell invasive cancer, cancer with low responsiveness to immune checkpoint inhibitors, and STING-associated vasculopathy with onset in infancy (SAVI).

[0048] The composition of the present invention contains both the compound of Formula 1 and a cyclic-dinucleotide, and can be administered in combination to a subject.

[0049] The term "co-administration" in the present invention means that the active ingredients are used simultaneously or sequentially.

[0050] In the present invention, it was confirmed that the compound of Formula 1 and cyclic dinucleotide were used together to provide high activity even at low concentrations of cyclic dinucleotide.

[0051] The composition may additionally comprise an acceptable carrier, but is not particularly limited thereto.

[0052] The acceptable carriers are those commonly used in formulations, including, but not limited to, saline, sterile water, Ringer's solution, buffered saline, cyclodextrin, dextrose solution, maltodextrin solution, glycerol, ethanol, liposomes, etc., and may further include other common additives such as antioxidants and buffers, if necessary. In addition, the composition may be formulated into injection forms such as aqueous solutions, suspensions, emulsions, pills, capsules, granules, or tablets by additionally adding diluents, dispersants, surfactants, binders, lubricants, etc. Suitable pharma- ceutical acceptable carriers and formulations may be formulated according to each component using the methods disclosed in Remington's literature. The pharmaceutical composition of the present invention is not particularly limited in dosage form, and may be formulated into injections, inhalants, skin topicals, etc.

[0053] One aspect of the present invention relates to a method for preventing or treating a disease, the method comprising administering the composition to a subject for treatment or prevention. Specifically, the composition can be used to provide a method for preventing or treating any one of autoimmune diseases, including cancer, solid cancer, non-T cell invasive cancer, cancer with low responsiveness to immune checkpoint inhibitors, and STING-associated vasculopathy with onset in infancy (SAVI).

[0054] In one specific example of the present invention, the subject of the treatment or prevention has or is likely to have any one of the following autoimmune diseases: cancer, solid cancer, non-T cell invasive cancer, cancer with low responsiveness to immune checkpoint inhibitors, and STING-associated vasculopathy with onset in infancy (SAVI).

[0055] The compositions can be administered in pharma- ceutically effective amounts to a subject for treatment or prophylaxis.

[0056] The term "pharmacologically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to any medical treatment, and the effective dose level can be determined depending on factors including the type and severity of the disease, age, sex, activity of the drug, sensitivity to the drug, time of administration, route of administration and excretion rate, duration of treatment, concurrently used drugs, and other factors well known in the medical art.

[0057] The composition can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents. It can also be administered singly or multiple times. It is important to administer an amount that provides maximum efficacy with minimal side effects while taking into account all of the above factors, which can be easily determined by those skilled in the art.

[0058] In addition, the composition can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally or topically) depending on the desired method, and the dosage varies depending on the condition and weight of the patient, the degree of disease, the drug form, the route and time of administration, but can be appropriately selected by one skilled in the art.

[0059] As a specific example, the composition can generally be administered in an amount of 0.001 to 1000 mg / kg, more specifically 0.05 to 200 mg / kg, and most specifically 0.1 to 100 mg / kg, once or several times a day; however, a preferred dosage can be appropriately selected by one skilled in the art depending on the condition and body weight of the individual, the severity of the disease, the drug form, and the route and duration of administration. EXAMPLES

[0060] Hereinafter, one or more specific examples will be described in more detail with reference to examples. However, these examples are merely for illustrative purposes and are not intended to limit the scope of the present invention.

[0061] 1 H and 13 C NMR spectra were recorded using a JEOL ECZ-600R (JEOL Ltd, Japan) and chemical shifts were measured in ppm downfield range of an internal tetramethylsilane standard.

[0062] Multiplicities are denoted as follows: s (singlet); d (doublet); t (triplet); q (quartet); m (multiplet); dd (doublet of doublet); ddd (doublet of doublet of doublet); dt (doublet of triplet); td (triplet of doublet); brs (broad singlet).

[0063] Coupling constants were recorded in Hz. Routine mass analyses were performed on an LC / MS system equipped with a reversed-phase column (C-18, 50Υ 2.1 mm, 5 μm) and a photodiode analytical detector using electrospray ionization (ESI) or atmospheric pressure chemical ionization (APCI).

[0064] The molecular weight of the compounds was confirmed by high-resolution mass spectrometry (LRMS). LRMS analysis was performed using an LCMS-2020 (Shimadzu, Japan).

[0065] Working Example Example 1: Preparation of Compound 1 Example 1-1: Preparation of (1-bromo-7-(trifluoromethyl)indolizin-3-yl)(4-(trifluoromethyl)phenyl)methanone (IA-B) [ka]

[0066] IA-E: The product was synthesized according to Reaction Scheme 1-1. Specifically, dimethylformamide (DMF, 10.0 mL) containing 4-(trifluoromethyl)pyridine (637 μL, 5.50 mmol) and 2-bromo-1-[4-(trifluoromethyl)-phenyl]ethane-1-one (1.54 g, 5.70 mmol) was stirred at 100° C. overnight, and then ethyl acrylate (293 μL, 2.75 mmol), copper(II) acetate monohydrate (1.64 g, 8.25 mmol), and sodium acetate (1.35 g, 16.5 mmol) were added and stirred at 100° C. for 16 hours. After completion of the reaction, monitored by TLC, copper acetate was removed by filtration through a celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water and the organic material was extracted with DCM three times. The combined organic extracts were dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1-15% EtOAc in hexane) to give compound IA-E (518 mg, 1.20 mmol, 43.8% yield) as a yellow solid.

[0067] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3) δ 10.0 (d, J = 7.2 Hz, 1H), 8.70 (s, 1H), 7.91 (d, J = 7.6 Hz 2H), 7.82 (s, 1H), 7.79 (d, J = 8.0 Hz, 2H), 7.23 (d, J = 7.2 Hz, 1H), 4.40 (q, J = 7.2 Hz, 2H), 1.41 (t, J = 7.2 Hz, 3H); 13 C NMR(100 MHz, CDCl3), δ 184.0, 162.8, 141.9, 137.7, 133.3, 132.6, 129.3, 128.9, 125.3, 124.7, 124.0, 122.6, 122.0, 121.2, 117.1, 110.9, 108.9, 60.6, 14.4.

[0068] IA-B IA-E (517.9 mg, 1.206 mmol) in methanol (10 mL) was added with KOH (5386 mg, 96.00 mmol) and stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IA-A as a brown solid.

[0069] The obtained compound IA-A was used immediately in the next step without further purification. Sodium bicarbonate (302.4 mg, 3.600 mmol) was added to DMF (10.0 mL) containing IA-A, and NBS (320.3 mg, 1.800 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IA-B (434.1 mg, 0.99 mmol, 82.9% yield) as a yellow solid.

[0070] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ 95.5 (d, J = 7.2 Hz, 1H), 7.90 (s, 2H), 7.87 (s, 1H), 7.78 (d, J = 8.0 Hz, 2H), 7.40 (s, 1H), 7.13 (d, J = 7.2 Hz, 1H); 13 C NMR(100 MHz, NNN) δ 183.1, 142.4, 135.0, 133.1, 129.2, 127.6, 126.6, 125.6, 125.5, 124.4, 123.0, 121.7, 115.4, 110.4, 93.0; LRMS (ESI) m / z calcd for C 17 H8BrF6NO [M+Na] + : 435.0, found : 436.3.

[0071] Example 1-2: Preparation of Compound 1 To a solution of IA-B (50.4 mg, 0.11 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (88.0 mg, 0.46 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (49.0 mg, 0.46 mmol) were added and stirred at 100° C. for 12 h. After completion of the reaction, which was monitored by TLC, it was washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate 25%) to give compound 1 (50.0 mg, 0.09 mmol, 86.7% yield) as a yellow solid. [ka]

[0072] The physical properties of the compound 1 prepared in Example 1 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.07 (d, J = 7.6 Hz, 1H), 8.11 (s, 1H), 7.95 (d, J = 8.8 Hz, 2H), 7.80 (d, J = 8.8 Hz, 2H), 7.74 (d, J = 8.4 Hz, 2H), 7.66 (s, 1H), 7.64 (s, 1H), 7.52 (s, 1H), 7.18 (dd, J = 7.4 Hz, 2 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 183.9, 142.9, 137.1, 134.4, 133.4, 133.1, 129.5, 129.2, 128.3, 127.3, 127.0, 126.2, 126.0, 125.6, 125.1, 124.5, 123.2, 122.8, 122.4, 121.8, 119.2, 115.3, 110.4; LRMS (ESI) m / z calcd for C 24 H 13 F9NO [M+H] + : 502.08; found: 502.10.

[0073] Example 2: Preparation of Compound 2 In Example 1-2, an indolizine derivative compound (48.4 mg, 0.10 mmol, 88.5% yield) was produced in the same manner as in Example 1, except that 4-acetylphenyl boronic acid (75.0 mg, 0.46 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (49.0 mg, 0.46 mmol) were added to a solution containing IA-B (50.2 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1. [ka]

[0074] The physical properties of the compound 2 prepared in Example 2 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.06 (d, J = 7.6 Hz, 1H), 8.15 (s, 1H), 8.07 (d, J = 6.8 Hz, 2H), 7.95 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 6.8 Hz, 2H), 7.54 (s, 1H), 7.18 (dd, J = 7.6 Hz, 2 Hz, 1H), 2.65(s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.2, 183.9, 142.9, 138.2, 135.8, 134.4, 133.0, 129.5, 129.3, 129.2, 128.0, 127.3, 126.9, 125.9, 125.6, 124.5, 123.3, 122.4, 121.8, 119.4, 115.5, 115.4, 110.4, 26.9; LRMS (ESI) m / z calcd for C 25 H 16 F6NO2[M+H] + : 476.10; found: 476.15.

[0075] Example 3: Preparation of Compound 3 In Example 1-2, an indolizine derivative compound (48.7 mg, 0.11 mmol, 96.0% yield) was produced in the same manner as in Example 1, except that phenylboronic acid (57.0 mg, 0.46 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (49.0 mg, 0.46 mmol) were added to a solution containing IA-B (51.2 mg, 0.11 mmol) and mixed with DMF and water in a 2:1 ratio. [ka]

[0076] The physical properties of the compound 3 prepared in Example 3 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.05 (d, J = 7.6 Hz, 1H), 8.14 (s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.55 (s, 1H), 7.53 (d, J = 3.6 Hz, 2H), 7.49 (d, J = 3.2 Hz, 2H), 7.39 (d, J = 7.2 Hz, 1H), 7.14 (dd, J = 7.4 Hz, 2.4 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 183.7, 143.1, 134.4, 133.3, 133.2, 132.9, 129.3, 129.2, 128.1, 127.5, 126.6, 125.8, 125.5, 125.4, 125.1, 124.7, 122.9, 122.0, 120.9, 115.7, 110.1; HRMS (ESI) m / z calcd for C 23 H 14 F6NO [M+H] + : 434.0980; found: 434.0979.

[0077] Example 4: Preparation of Compound 4 In Example 1-2, an indolizine derivative compound (51.4 mg, 0.11 mmol, 94.8% yield) was produced in the same manner as in Example 1, except that 4-methoxyphenyl boronic acid (71.0 mg, 0.46 mmol), tetrakis(triphenyl phosphine)palladium (231 mg, 20.0 mol%), and sodium carbonate (49.0 mg, 0.46 mmol) were added to a solution containing IA-B (51.0 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1. [ka]

[0078] The physical properties of compound 4 prepared in Example 4 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.02 (d, J = 6.8 Hz, 1H), 8.08 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.46 (s, 1H), 7.42 (d, J = 5.0 Hz, 2H), 7.10 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 7.02 (dd, J = 6.8 Hz, 2.0 Hz, 2H), 3.86 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 183.5, 159.0, 143.1, 134.4, 133.0, 132.7, 129.2, 127.6, 126.3, 125.9, 125.6, 125.5, 125.4, 125.4, 125.1, 125.6, 122.7, 122.4, 121.9, 120.7, 115.7, 114.6, 114.1, 109.9; 24 H 16 F6NO2for [M+H] +found: 464.10.

[0079] Example 5: Preparation of Compound 5 In Example 1-2, an indolizine derivative compound (51.5 mg, 0.10 mmol, 91.6% yield) was produced in the same manner as in Example 1, except that 4-(dimethylamino)phenyl boronic acid (78.0 mg, 0.47 mmol), tetrakis(triphenyl phosphine)palladium (231 mg, 20.0 mol%), and sodium carbonate (50 mg, 0.47 mmol) were added to a solution containing IA-B (51.4 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1. [ka]

[0080] The physical properties of the compound 5 prepared in Example 5 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.01 (d, J = 7.6 Hz, 1H), 8.12 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.41 (d, J = 5.0 Hz, 2H), 7.40 (s, 1H), 7.09 (d, J = 7.6 Hz, 1H), 6.84 (d, J = 7.6 Hz, 2H), 3.02 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 183.4, 149.8, 143.3, 134.3, 132.9, 132.6, 129.2, 129.1, 128.8, 125.9, 125.7, 125.5, 125.1, 124.7, 122.6, 122.4, 122.0, 121.5, 121.4, 121.0, 116.0, 115.9, 112.9, 109.7, 40.6; LRMS (ESI) m / z calcd for C 25 H 19 F6N2O [M+H] + : 477.13; found: 477.35.

[0081] Example 6: Preparation of Compound 6 Example 6-1: (1-bromo-7-(trifluoromethyl)indolizin-3-yl)(phenyl)methanone(IC-B) [ka]

[0082] IC-E: Synthesized as in Reaction Scheme 1-2. Specifically, 4(trifluoromethyl)pyridine (348μL, 3.00mmol) and 2-bromoacetophenone (627mg, 3.15mmol) in DMF (7.0mL) were stirred at 100℃ overnight, and then ethyl acrylate (160μL, 0.50mmol), copper(II) acetate monohydrate (898mg, 1.50mmol) and sodium acetate (738mg, 9.00mmol) were added and stirred at 100℃ for 16 hours. After completion of the reaction and monitoring by TLC, the copper acetate was removed by filtration through a Celite pad, and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and then concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1–15% hexane with EtOAc) to give compound IC-E (481.9 mg, 1.3 mmol, 88.9% yield) as a yellow solid.

[0083] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ 9.88 (d, J = 7.6 Hz, 1H), 8.59 (s, 1H), 7.78 (s, 1H), 7.74 (d, J = 6.8 Hz, 2H), 7.53 (t, J = 7.4 Hz, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.10 (dd, J = 7.4 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 1.37 (t, J = 7.0 Hz, 3H) 13 C NMR(100 MHz, CDCl3) δ 185.3, 163.0, 138.8, 137.2, 131.7, 129.2, 128.8, 128.5, 128.3, 128.2, 128.0, 124.2, 123.2, 121.5, 117.0, 110.4, 108.5, 60.5, 14.5 LRMS (ESI) m / z calcd for C 19 H 14 F3NO [M+Na] + : 361.1, found : 362.1.

[0084] IC-B: KOH (519 mg, 10.0 mmol) was added to IC-E (481.9 mg, 1.3 mmol) in methanol (10 mL) and stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IC-A as a white solid.

[0085] The obtained compound IC-A was used immediately in the next step without further purification. Sodium bicarbonate (162.4 mg, 1.9 mmol) was added to IC-A in DMF (10.0 mL), and NBS (172.0 mg, 0.9 mmol) was added in portions at 0 ° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane = 1:8-ethyl acetate 12%) to obtain compound IC-B (219.2 mg, 0.595 mmol, 99.2% yield) as a yellow solid.

[0086] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ 9.96 (d, J = 7.6 Hz, 1H), 7.90 (s, 1H), 7.79 (d, J = 8.0 Hz, 2H), 7.59 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.4 Hz, 1H), 7.46 (s, 1H), 7.09 (d, J = 7.6 Hz, 1H) 13C NMR(100 MHz, CDCl3) δ 185.4, 139.1, 134.2, 131.7, 128.9, 128.8, 128.3, 127.4, 126.1, 125.7, 124.4, 123.2, 121.7, 115.1, 109.8, 92.3 LRMS (ESI) m / z calcd for C 16 H9BrF3NO [M+Na] + : 367.0, found : 368.0.

[0087] Example 6-2: Preparation of Compound 6 To a solution of IC-B (51.2 mg, 0.14 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (106 mg, 0.55 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (59.0 mg, 0.55 mmol) were added and stirred at 100 °C for 5 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 6 (54.0 mg, 0.12 mmol, 89.0% yield) as a yellow solid. [ka]

[0088] The physical properties of compound 6 prepared in Example 6 are as follows. 1H NMR (400 MHz, CDCl3) δ 10.05 (d, J = 7.6 Hz, 1H), 8.09 (s, 1H), 7.85 (d, J = 8.2 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 6.8 Hz, 1H), 7.57 (s, 1H), 7.54 (d, J = 7.6 Hz, 2H), 7.14 (dd, J = 7.4 Hz, 2.0 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 185.5, 139.8, 137.5, 133.9, 131.8, 129.5, 129.1, 128.6, 128.3, 126.4, 126.2, 126.2, 126.0, 125.8, 123.8, 118.7, 115.3, 110.0, 110.0, 47.1, 34.7; LRMS (ESI) m / z calcd for C 23 H 14 F6NO [M+H] + : 434.09; found: 434.30.

[0089] Example 7: Preparation of Compound 7 In Example 6-2, 4-acetylphenylboronic acid (65.6 mg, 0.4 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (42.4 mg, 0.4 mmol) were added to a solution containing IC-B (36.9 mg, 0.1 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100°C for 6 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (38.1 mg, 0.09 mmol, 93.5% yield) was produced in the same manner as in Example 6. [ka]

[0090] The physical properties of the compound 7 prepared in Example 7 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.03 (d, J = 7.2 Hz, 1H), 8.13 (s, 1H), 8.06 (d, J = 8.4 Hz, 2H), 7.84 (d, J = 8.4 Hz, 2H), 7.64 (d, J = 8.0 Hz, 2H), 7.59 (s, 1H), 7.52 (d, J = 7.4 Hz, 3H), 7.12 (dd, J = 7.2 Hz, 1.6 Hz, 1H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.5, 185.6, 139.9, 138.8, 135.8, 134.1, 132.0, 129.7, 129.5, 129.3, 128.7, 128.1, 126.8, 126.5, 126.1, 124.9, 123.9, 122.2, 119.1, 115.6, 115.6, 110.1, 110.2, 27.1; LRMS (ESI) m / z calcd for C 24 H 17 F3NO2[M+H] + : 408.11; found: 408.10.

[0091] Example 8: Preparation of Compound 8 In Example 6-2, an indolizine derivative compound (79.8 mg, 0.10 mmol, 94.5% yield) was produced in the same manner as in Example 6, except that phenylboronic acid (53.7 mg, 0.44 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (46.6 mg, 0.44 mmol) were added to a solution containing IC-B (40.5 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 12 hours. [ka]

[0092] The physical properties of the compound 8 prepared in Example 8 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.04 (d, J = 7.2 Hz, 1H), 8.12 (s, 1H), 7.86 (d, J = 7.2 Hz, 2H), 7.58 (d, J = 6.0 Hz, 1H), 7.52 (m, 7H), 7.38 (d, J = 7.6 Hz, 1H), 7.10 (dd, J = 7.6 Hz, 1.6 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 185.3, 140.0, 133.8, 133.7, 131.5, 129.2, 129.1, 129.1, 128.4, 128.1, 127.3, 126.0, 125.8, 125.7, 123.4, 122.1, 120.4, 115.7, 115.6, 109.6, 47.0, 34.6; LRMS (ESI) m / z calcd for C 22 H 15 F3NO [M+H] + found: 366.10.

[0093] Example 9: Preparation of Compound 9 In Example 6-2, an indolizine derivative compound (57.6 mg, 0.14 mmol, 100% yield) was produced in the same manner as in Example 6, except that 4-methoxyphenylboronic acid (79.0 mg, 0.52 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (55.1 mg, 0.52 mmol) were added to a solution containing IC-B (47.9 mg, 0.13 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 8 hours. [ka]

[0094] The physical properties of the compound 9 prepared in Example 9 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.02 (d, J = 7.6 Hz, 1H), 8.07 (s, 1H), 7.85 (d, J = 6.8 Hz, 2H), 7.58 (d, J = 7.2 Hz, 1H), 7.52 (d, J = 8.0 Hz, 2H), 7.48 (s, 1H), 7.46 (d, J = 8.8 Hz, 2H), 7.07 (dd, J = 7.2 Hz, 1.6 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 3.86 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 185.1, 158.8, 139.9, 133,6, 131.4, 129.2, 129.0(2), 128.3, 125.9, 125.6, 125.5, 125.4, 125.2, 123.1, 120.1, 115.6, 115.5, 114.5, 109.4, 109.3, 55.5; LRMS (ESI) m / z calcd for C 23 H 17 F3NO2[M+H] + : 396.11; found: 396.10.

[0095] Example 10: Preparation of Compound 10 In Example 6-2, an indolizine derivative compound (43.5 mg, 0.10 mmol, 99.7% yield) was produced in the same manner as in Example 6, except that 4-(dimethylamino)phenylboronic acid (45.5 mg, 0.43 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (108 mg, 1.01 mmol) were added to a solution containing IC-B (39.5 mg, 0.10 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 19 hours. [ka]

[0096] The physical properties of the compound 10 prepared in Example 10 are as follows. 1 H NMR (400 MHz, CDCl3) δ 10.02 (d, J = 7.2 Hz, 1H), 8.11 (s, 1H), 7.87 (d, J = 7.2 Hz, 2H), 7.57 (d, J = 7.2 Hz, 2H), 7.52 (d, J = 7.6 Hz, 1H), 7.48 (s, 1H), 7.43 (d, J = 8.8 Hz, 2H), 7.05 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 6.87 (d, J = 8.0 Hz, 2H), 3.02 (s, 6H); 13 C NMR (100 MHz, CDCl3) δ 185.2, 166.7, 149.8, 140.3, 133.8, 131.5, 129.2, 129.0, 128.4, 127.3, 125.8, 125.4, 125.1, 125.0, 123.2, 122.3, 121.0, 116.1, 116.0, 113.2, 109.4, 47.1, 41.0, 34.7; LRMS (ESI) m / z calcd for C 24 H 20 F3N2O [M+H] + : 409.14; found: 409.20.

[0097] Example 11: Preparation of Compound 11 Example 11-1: (1-bromo-7-(trifluoromethyl)indolizin-3-yl)(4-methoxyphenyl)methanone (ID-B) [ka]

[0098] ID-E: The product was synthesized as in Reaction Scheme 1-3. Specifically, 4(trifluoromethyl)pyridine (695 μL, 6.00 mmol) and 2-bromo-4-methoxyacetophenone (1.44 g, 6.30 mmol) were stirred in DMF (10.0 mL) at 100 ° C overnight, and then ethyl acrylate (320 μL, 3.00 mmol), copper (II) acetate monohydrate (1.79 g, 9.00 mmol) and sodium acetate (1.47 g, 18.0 mmol) were added and stirred at 100 ° C for 16 hours. After completion of the reaction, which was monitored by TLC, the copper acetate was removed by filtration through a Celite pad, and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted with DCM three times. The combined organic extracts were dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1-15% hexane with EtOAc) to give compound ID-E (1.02 g, 2.63 mmol, 87.6% yield) as a yellow solid.

[0099] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ 9.93 (d, J = 7.2 Hz, 1H), 8.69 (s, 1H), 7.89 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.18 (d, J = 7.4Hz, 1H), 7.03 (d, J = 8.8 Hz, 2H), 4.41 (d, J = 7.2 Hz, 2H), 3.92 (s, 3H), 1.42 (d, J = 6.6 Hz, 3H); 13C NMR(100 MHz, CDCl3) δ 184.1, 163.2, 162.7, 137.0, 131.3, 131.1, 129.2, 127.9, 127.8, 127.6, 124.3, 123.3, 121.6, 121.3, 116.9, 113.6, 110.1, 108.2, 60.5, 55.4, 14.5; LRMS (ESI) m / z calcd for C 20 H 16 F3NO4[M+Na] + : 391.1, found : 392.2.

[0100] ID-B KOH (5.91 g, 105 mmol) was added to methanol (18 mL) containing ID-E (1.02 g, 2.62 mmol) and the mixture was stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound ID-A as a white solid.

[0101] The obtained compound ID-A was used immediately in the next step without further purification. Sodium bicarbonate (660 mg, 7.86 mmol) was added to ID-A in DMF (10.0 mL), and NBS (699 mg, 3.93 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound ID-B (0.93 g, 2.36 mmol, 90.0% yield) as a yellow solid.

[0102] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3) δ 9.88 (d, J = 8.0 Hz, 1H), 7.88 (s, 1H), 7.82 (d, J = 8.8 Hz, 2H), 7.46 (s, 1H), 7.05 (d, J = 7.6 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 3.90 (s, 3H); 13 C NMR(100 MHz, CDCl3) δ 183.3, 162.5, 133.8, 131.5, 131.1, 128.8, 126.7, 125.6, 125.3. 124.4, 123.3, 121.7, 121.3, 115.1, 109.4, 62.0, 55.5.

[0103] Example 11-2: Preparation of Compound 11 To a solution of ID-B (105.7 g, 0.26 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (202 mg, 1.06 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (112 mg, 1.06 mmol) were added and stirred at 100 °C for 5 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 11 (90.2 mg, 0.19 mmol, 73.4% yield) as a yellow solid. [ka]

[0104] The physical properties of the compound 1 prepared in Example 1 are as follows. 1H NMR (400 MHz, CDCl3) δ 9.91 (d, J = 7.2 Hz, 1H), 8.05 (s, 1H), 7.65 (s, 1H), 7.51 (m, 6H), 7.37 (t, J = 7.2 Hz, 2H), 6.98 (dd, J = 7.4 Hz, 1.6 Hz, 1H), 2.63 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 187.4, 133.6, 132.8, 129.0, 128.8, 127.9, 127.1, 125.2, 124.9, 124.7, 123.4, 122.9, 122.0, 119.9, 115.4, 115.4, 109.3, 109.2, 27.7. HRMS (ESI) m / z calcd for C 24 H 16 F6NO2[M+H] + : 464.1085; found: 464.1080.

[0105] Example 12: Preparation of Compound 12 In Example 11-2, 4-acetylphenylboronic acid (155 mg, 0.94 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (100 mg, 0.94 mmol) were added to a solution containing ID-B (94.3 mg, 0.23 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 9 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (48.4 mg, 0.10 mmol, 88.5% yield) was produced in the same manner as in Example 11. [ka]

[0106] The physical properties of compound 12 prepared in Example 12 are as follows. 1H NMR (400 MHz, CDCl3) δ 9.96 (d, J = 7.6 Hz, 1H), 8.12 (s, 1H), 8.07 (t, J = 8.2 Hz, 3H), 7.88 (d, J = 9.2 Hz, 2H), 7.72 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.4 Hz, 1H), 7.60 (s, 1H), 7.09 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 7.03 (d, J = 8.8 Hz, 1H), 3.91 (s, 3H), 2.66 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.0, 183.8, 162.4, 143.8, 138.4, 136.2, 135.2, 133.0, 131.8, 131.1, 129.0, 128.7, 127.5, 127.1, 125.4, 124.9, 124.5, 123.6, 121.8, 118.3, 115.1, 113.5, 109.2, 55.4, 26.6; LRMS (ESI) m / z calcd for C 25 H 19 F3NO3[M+H] + : 437.12; found: 438.15.

[0107] Example 13: Preparation of Compound 13 In Example 11-2, an indolizine derivative compound (97.6 mg, 0.24 mmol, 100% yield) was produced in the same manner as in Example 11, except that phenylboronic acid (115 mg, 0.94 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (100 mg, 0.94 mmol) were added to a solution containing ID-B (94.0 mg, 0.23 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 12 hours. [ka]

[0108] The physical properties of compound 13 prepared in Example 13 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.6 Hz, 1H), 8.11 (s,1H), 7.88 (d, J = 8.8 Hz, 2H), 7.56(m, 3H), 7.49 (t, J = 7.8 Hz, 2H), 7.38 (m, 1H), 7.06 (dd, J = 7.8 Hz, 2.0 Hz, 1H), 7.02 (d, J = 8.8 Hz, 2H), 3.91 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 184.5, 162.7, 134.1, 133.6, 132.7, 131.6, 129.4, 129.3, 128.4, 127.5, 125.8, 125.5, 125.4, 125.1, 123.7, 122.4, 120.3, 115.9, 115.8, 114.0, 109.6, 109.5, 55.9; LRMS (ESI) m / z calcd for C 23 H 17 F3NO2[M+H] + : 396.11; found: 396.10.

[0109] Example 14: Preparation of Compound 14 In Example 11-2, an indolizine derivative compound (125.6 mg, 0.29 mmol, 98.4% yield) was produced in the same manner as in Example 11, except that 4-methoxyphenylboronic acid (182 mg, 1.20 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (127 mg, 1.20 mmol) were added to a solution containing ID-B (120 mg, 0.30 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 8 hours. [ka]

[0110] The physical properties of compound 14 prepared in Example 14 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.93 (d, J = 7.6 Hz, 1H), 8.05 (s, 1H), 7.87 (d, J = 8.8 Hz, 2H), 7.49 (s, 1H), 7.47 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 6.4 Hz, 3H), 7.01 (d, J = 6.4 Hz, 2H), 3.90 (s, 3H), 3.87 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 183.8, 162.2, 158.7, 133.0, 132.2, 131.1, 129.0, 128.8, 126.0, 124.9, 124.8, 124.7, 124.6, 123.1, 122.1, 119.7, 115.4, 115.4, 114.4, 113.5, 108.8, 108.9, 55.4, 55.3; LRMS (ESI) m / z calcd for C 24 H 19 F3NO3[M+H] + : 426.12; found: 426.15.

[0111] Example 15: Preparation of Compound 15 In Example 11-2, an indolizine derivative compound (151 mg, 0.34 mmol, 100% yield) was produced in the same manner as in Example 11, except that 4-(dimethylamino)phenylboronic acid (220 mg, 1.33 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (141 mg, 1.33 mmol) were added to a solution containing ID-B (132.8 mg, 0.33 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 9 hours. [ka]

[0112] The physical properties of compound 15 prepared in Example 15 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.92 (d, J = 7.6 Hz, 1H), 8.08 (s, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.48 (s, 1H), 7.43 (d, J = 8.8 Hz, 2H), 7.01 (d, J = 8.8 Hz, 3H), 6.85 (d, J = 8.8 Hz, 2H), 3.90 (s, 3H), 3.01 (s, 6H); 13 C NMR (100 MHz, CDCl3) δ 183.8, 162.1, 149.5, 133.0, 132.4, 131.1, 128.7, 128.6, 127.5, 124.8, 124.5, 124.4, 124.2, 123.8, 123.0, 122.1, 121.4, 120.5, 119.4, 115.7, 113.4, 112.7, 108.7, 55.4, 40.5; LRMS (ESI) m / z calculation for C 25 H 22 F3N2O2[M+H] + : 439.16; found: 439.15.

[0113] Example 16: Preparation of Compound 16 Example 16-1: (1-bromo-7-(trifluoromethyl)indolizin-3-yl)(4-(diethylamino)phenyl)methanone(IE-B) [ka]

[0114] IE-E: Synthesized as in Reaction Scheme 1-4. Specifically, 4(trifluoromethyl)pyridine (695 μL, 6.00 mmol) and 2-Bromo-4'-(diethylamino)acetophenone (1.70 mL, 6.30 mmol) in DMF (6.0 mL) were stirred at 100° C. overnight, and then ethyl acrylate (320 μL, 3.00 mmol), copper(II) acetate monohydrate (1.79 g, 9.00 mmol) and sodium acetate (1.47 g, 18.0 mmol) were added and stirred at 100° C. for 16 hours. After completion of the reaction, which was monitored by TLC, the copper acetate was removed by filtration through a Celite pad, and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted with DCM three times. The combined organic extracts were dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1-15% hexane with EtOAc) to give compound IE-E (1.12 g, 2.60 mmol, 86.9% yield) as a yellow solid.

[0115] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ 9.83 (d, J = 8.0 Hz, 1H), 8.66 (s, 1H), 7.91 (s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 7.4 Hz, 1H), 6.72 (d, J = 5.4 Hz, 2H), 4.41 (q, J = 6.9, 2H), 3.46 (q, J = 6.6 Hz, 4H), 1.43 (t, J = 5.2, 3H), 1.25 (d, J = 5.5 Hz, 6H); 13C NMR(100 MHz, CDCl3) δ 182.8, 163.1, 150.4, 136.1, 131.4, 128.9, 126.7, 126.4, 126.1, 124.6, 124.3, 123.6, 121.6, 116.5(2), 109.8, 109.1, 109.2, 107.4, 60.0, 44.2, 14.3, 12.3; LRMS (ESI) m / z calcd for C 23 H 23 F3N2O3[M+Na] + : 432.2, found : 433.2.

[0116] IE-B: IE-E (1.12 g, 2.60 mmol) in methanol (10 mL) was added with KOH (5.85 g, 104 mmol) and stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IE-A as a white solid.

[0117] The obtained compound IE-A was used immediately in the next step without further purification. Sodium bicarbonate (655 mg, 7.80 mmol) was added to IE-A in DMF (10.0 mL), and NBS (694 mg, 3.90 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IE-B (829 mg, 1.88 mmol, 72.6% yield) as a yellow solid.

[0118] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3), δ 9.83 (d, J = 8.0 Hz, 1H), 8.66 (s, 1H), 7.91 (s, 1H), 7.84 (d, J = 8.8 Hz, 2H), 7.11 (d, J = 7.4 Hz, 1H), 6.72 (d, J = 5.4 Hz, 2H), 4.41 (q, J = 6.9, 2H), 3.46 (q, J = 6.6 Hz, 4H), 1.43 (t, J = 5.2, 3H), 1.25 (d, J = 5.5 Hz, 6H); 13 C NMR(100 MHz, CDCl3) δ 182.0, 152.9, 135.2, 134.2, 133.9, 129.0, 128.8, 126.9, 126.0, 125.7, 124.6, 123.2, 122.3, 121.9, 120.1, 115.3, 92.5, 46.5, 12.8, 12.7.

[0119] Example 16-2: Preparation of Compound 16 To a solution of IE-B (54.0 mg, 0.12 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (94.4 mg, 0.49 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (52.7 mg, 0.49 mmol) were added and stirred at 100 °C for 5 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 16 (43.1 mg, 0.08 mmol, 68.8% yield) as a yellow solid. [ka]

[0120] The physical properties of compound 16 prepared in Example 16 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.6 Hz, 1H), 8.07 (s, 1H), 7.83 (d, J = 8.6 Hz, 1H), 7.76 (s, 1H), 7.74 (d, J = 5.6 Hz, 1H), 7.67 (m, 4H), 7.64 (s, 1H), 7.15 (d, J = 8.4 Hz, 1H), 7.09 (dd, J = 7.6 Hz, 2.0 Hz, 1H), 3.00 (q, J = 6.9 Hz, 4H), 0.98 (t, J = 7.0 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 184.3, 152.6, 145.1, 137.7, 133.6, 133.5, 133.2, 132.5, 130.1, 129.4, 129.3, 129.0(2), 128.3, 126.3, 126.2(2), 125.7, 125.6, 125.5, 125.1, 124.0, 120.0, 118.4, 46.0, 12.4; 27 H 23 F6N2O [M+H] + : 505.16; found 505.20.

[0121] Example 17: Preparation of Compound 17 In Example 16-2, 4-acetylphenylboronic acid (74.2 mg, 0.45 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (48.0 mg, 0.45 mmol) were added to a solution containing IE-B (49.7 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 9 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (9.70 mg, 0.02 mmol, 18% yield) was produced in the same manner as in Example 16. [ka]

[0122] The physical properties of compound 17 prepared in Example 17 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.6 Hz, 1H), 8.12 (s, 1H), 8.08 (d, J = 8.4 Hz, 2H), 7.91 (d, J = 2.0 Hz, 1H), 7.30 (m, 2H), 7.67 (d, J = 8.8 Hz, 2H), 7.63 (s, 1H), 7.00 (m, 2H), 3.29 (q, J = 7.0 Hz, 4H), 2.66 (s, 3H), 1.14 (t, J = 7.2 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 197.2, 183.1, 151.4, 138.6, 135.6, 133.6, 133.3, 132.1, 129.2, 128.7, 128.2, 127.9, 125.2, 121.5, 118.8, 46.1, 29.9, 26.9, 12.7; LRMS (ESI) m / z calcd for C 28 H 26 F3N2O2[M+H] + : 479.19; found 479.25.

[0123] Example 18: Preparation of Compound 18 In Example 16-2, an indolizine derivative compound (39.9 mg, 0.09 mmol, 80.1% yield) was produced in the same manner as in Example 16, except that phenylboronic acid (55.0 mg, 0.45 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (49.0 mg, 0.45 mmol) were added to a solution containing IE-B (50.0 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 9 hours. [ka]

[0124] The physical properties of compound 18 prepared in Example 18 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.96 (d, J = 7.2 Hz, 1H), 8.11 (s, 1H), 7.81 (s, 1H), 7.66 (s, 1H), 7.59 (t, J = 7.6 Hz, 3H), 7.50 (t, J = 6.8 Hz, 1H), 7.40 (m, 2H), 7.32 (d, J = 6.6 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 7.05 (d, J = 7.2 Hz, 1H), 3.03 (q, J = 6.5 Hz, 4H), 1.01 (t, J = 6.6Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 184.7, 152.6, 141.7, 135.1, 134.2, 133.6, 133.5, 132.5, 129.7, 129.4, 129.3, 128.8, 128.7, 128.4, 127.4, 127.1, 125.3, 125.2, 124.0, 120.2, 119.8, 115.9, 109.4, 46.1, 12.6; LRMS (ESI) m / z calcd for C 26 H 24 F3N2O [M+H] + : 437.18; found 437.20.

[0125] Example 19: Preparation of Compound 19 In Example 16-2, an indolizine derivative compound (44.8 mg, 0.09 mmol, 78.7% yield) was produced in the same manner as in Example 16, except that 4-methoxyphenylboronic acid (74.0 mg, 0.48 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (52.0 mg, 0.48 mmol) were added to a solution containing IE-B (53.7 mg, 0.12 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 10 hours. [ka]

[0126] The physical properties of compound 19 prepared in Example 19 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.84 (d, J = 7.6 Hz, 1H), 8.02 (s, 1H), 7.86 (d, J = 9.2 Hz, 2H), 7.54 (s, 1H), 7.48 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 6.96 (dd, J = 7.6 Hz, 2.4 Hz, 1H), 6.71 (d, J = 9.2 Hz, 2H), 3.87 (s, 3H), 3.45 (q, J = 6.9 Hz, 4H), 1.23 (t, J = 7.2 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 184.0, 152.0, 141.0, 134.4, 133.6, 133.0, 132.8, 131.9, 129.0, 128.7, 128.2, 128.1, 127.8, 126.8, 126.5, 124.9, 124.7, 124.5, 123.3, 121.8, 119.6, 119.1, 115.2, 108.8, 45.4, 29.6, 12.0; LRMS (ESI) m / z calcd for C 27 H 26 F3N2O2[M+H] +: 467.19; found: 467.27.

[0127] Example 20: Preparation of Compound 20 In Example 16-2, an indolizine derivative compound (43.1 mg, 0.08 mmol, 72.4% yield) was produced in the same manner as in Example 16, except that 4-(dimethylamino)phenylboronic acid (88.0 mg, 0.52 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (55.5 mg, 0.52 mmol) were added to a solution containing IE-B (57.5 mg, 0.13 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 12 hours. [ka]

[0128] The physical properties of compound 20 prepared in Example 20 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.2 Hz, 1H), 8.10 (s, 1H), 7.81 (d, J = 2.4 Hz, 1H), 7.77 (d, J = 8.6 Hz, 1H), 7.61 (s, 1H), 7.52 (d, J = 8.8 Hz, 2H), 7.46 (d, J = 8.8 Hz, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.00 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 6.87 (d, J = 8.8 Hz, 1H), 6.79 (d, J = 8.8 Hz, 1H), 3.07 (q, J = 7.1 Hz, 4H), 3.03 (s, 3H), 3.00 (s, 3H), 1.01 (d, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 184.2, 151.8, 149.3, 149.0, 134.6, 132.7, 132.2, 129.0, 128.8, 128.6, 128.5, 128.1, 124.6, 124.2, 124.1, 123.8, 123.2, 121.9, 121.5, 120.1, 119.2, 115.5, 112.6, 112.1, 108.4, 45.1, 40.4, 11.9; LRMS (ESI) m / z calcd for C 28 H 29 F3N3O [M+H] + : 480.22; found 480.35.

[0129] Example 21: Production of Compound 21 Example 21-1: 1-(1-bromo-3-(4-(trifluoromethyl)benzoyl)indolizin-7-yl)ethanone(IF-B)

change

[0130] IF-E: Synthesized as in Reaction Scheme 1-5. Specifically, 4-acetylpyridine (394.6 μL, 3.567 mmol) and 2-bromo-4'-(trifluoromethyl)acetophenone (1.0 g, 3.8 mmol) were added to DMF (12.0 mL) at 80° C. for 4 hours, and then ethyl acrylate (193.6 μL, 1.79 mmol), copper (II) acetate monohydrate (2.14 g, 10.7 mmol) and sodium acetate (1.17 g, 14.3 mmol) were added and stirred at 100° C. for 16 hours. After completion of the reaction, the reaction was monitored by TLC, and the copper acetate was removed by filtration through a Celite pad, and the resulting filtrate was concentrated under vacuum. The resulting crude product was washed with water, and the organic material was extracted with DCM three times. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to give compound IF-E (556.5 mg, 77.3% yield) as a yellow solid.

[0131] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.87 (dd, J = 7.2, 1.2 Hz, 1H), 8.96 (s, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.79 (m, 3H), 7.61 (dd, J = 7.4, 2.4 Hz, 1H), 4.40 (q, J = 7.2 Hz, 2H), 1.42 (t, J = 7.2 Hz, 3H); 13C NMR(100 MHz, CDCl3) 195.6, 184.4, 163.5, 142.5, 138.8, 134.8,133.7, 133.3, 129.4, 129.1, 128.9, 125.8, 125.7 (2), 125.2, 123.4, 122.5, 121.6, 121.1, 113.1, 109.9 60.9, 26.6, 14.9; LRMS (ESI) m / z calcd for C 21 H 16 F3NO4[M+Na] + : 403.1, found : 404.2.

[0132] IF-B: IF-E (556.5 mg, 1.379 mmol) in methanol (5 mL) was added with KOH (2.21 g, 55.2 mmol) and stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was filtered, washed with water, and dried in a drying oven to obtain compound IF-A as a brown solid.

[0133] The obtained compound IF-A was used immediately in the next step without further purification. Sodium bicarbonate (350.3 mg, 4.170 mmol) was added to IF-A in DMF (10.0 mL), and NBS (259.6 mg, 1.459 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to obtain compound IF-B (358.6 mg, 63.4% yield) as a yellow solid.

[0134] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3), δ 9.87 (d, J = 7.4 Hz, 1H), 8.18 (s, 1H), 7.90 (d, J = 8.0 Hz, 2H), 7.79 (d, J = 8.0 Hz, 2H), 7.53 (dd, J = 7.4, 2 Hz, 1H), 7.39 (s, 1H), 2.72 (s, 3H); 13 C NMR(100 MHz, CDCl3) 195.2, 183.3, 142.7, 135.8, 133.5, 133.2, 132.8, 129.3, 128.5, 127.6, 125.7(2), 125.2, 123.5, 122.5, 119.2, 112.5, 94.5, 26.7; LRMS (ESI) m / z calcd for C 18 H 11 BrF3NO2[M+Na] + : 409.0, found : 410.0.

[0135] Example 21-2: Preparation of Compound 21 To a solution of IF-B (30.0 mg, 0.063 mmol) in 10:1 DMF and water, 4-trifluorophenylboronic acid (35.9 mg, 0.189 mmol), tetrakis(triphenylphosphine)palladium (15.0 mg, 0.013 mmol) and sodium carbonate (33.6 mg, 0.315 mmol) were added and stirred at 100 °C for 8 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to give compound 21 (28.6 mg, 95.4% yield) as a yellow solid. [ka]

[0136] The physical properties of compound 21 prepared in Example 21 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.97 (d, J = 7.4 Hz, 1H), 8.42(s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.75 (d, J = 8.0 Hz, 2H), 7.68 (d, J = 8.4 Hz, 2H), 7.55 (dd, J = 7.2 Hz, 1.6 Hz, 1H), 7.49 (s, 1H), 2.67(s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.3, 183.9, 143.1, 137.4, 135.3, 133.5, 133.1, 129.7, 129.4, 129.3, 128.7, 128.5, 126.3 (2), 125.8, 125.7 (2), 125.2, 123.7, 122.9, 122.5, 120.5, 119.1, 112.6, 26.8; LRMS (APCI) m / z calcd for C 25 H 16 F6NO2[M+H] + : 476.10; found: 476.59.

[0137] Example 22: Preparation of Compound 22 In Example 21-2, an indolizine derivative compound (27.3 mg, 96.3% yield) was produced in the same manner as in Example 21, except that 4-acetylphenylboronic acid (31.0 mg, 0.189 mmol), tetrakis(triphenylphosphine)palladium (15.0 mg, 0.013 mmol) and sodium carbonate (33.6 mg, 0.315 mmol) were added to a solution containing IF-B (30.0 mg, 0.063 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0138] The physical properties of compound 22 prepared in Example 22 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.97(d, J = 7.2 Hz, 1H), 8.46 (s, 1H), 8.08 (dd, J = 8.4 Hz, 1.6 Hz, 2H), 7.96 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 8.4 Hz, 1H), 7.80 (d, J = 8.4 Hz, 2H), 7.67 (dd, J = 6.6 Hz, 2.0 Hz, 2H), 7.55 (dd, J = 7.4 Hz, 1.6 Hz, 1H), 7.51 (s, 1H), 6.90(d, J = 8.4 Hz, 1H), 2.67 (dd, J = 7.6 Hz, 2.8Hz, 4H); 13 C NMR (100 MHz, CDCl3) δ 197.4, 196.9, 195.4, 184.0, 160.4, 143.1, 138.6, 135.9, 135.4, 133.5, 133.1, 132.8, 131.1, 130.5, 129.4 (2), 128.8, 128.2, 127.9, 125.9, 125.7 (2), 125.2, 123.8, 122.5, 120.8, 119.8, 119.3, 115.5, 112.6, 36.1, 27.1, 26.8, 26.7.LRMS (APCI) m / z calcd for C 26 H 19 F3NO3[M+H] + : 450.12; found: 450.63.

[0139] Example 23: Preparation of Compound 23 In Example 21-2, an indolizine derivative compound (23.6 mg, 91.9% yield) was produced in the same manner as in Example 21, except that 4-acetylphenylboronic acid (23.0 mg, 0.189 mmol), tetrakis(triphenylphosphine)palladium (15.0 mg, 0.013 mmol) and sodium carbonate (33.6 mg, 0.315 mmol) were added to a solution containing IF-B (30.0 mg, 0.063 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0140] The physical properties of compound 23 prepared in Example 23 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.94 (d, J = 8.0 Hz, 1H), 8.40 (s, 1H), 7.86 (d, J = 7.6 Hz, 2H), 7.75 (d, J = 8.4 Hz, 2H), 7.69 (d, J = 8.0 Hz, 2H), 7.62 t, J = 5.2 Hz, 1H), 7.51 (m, 4H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.4, 185.5, 140.0, 137.8, 134.7, 132.6, 131.8, 129.5, 129.2, 128.6 (2), 128.4, 126.3, 126.2, 125.8, 124.2, 120.1, 119.1, 112.2, 26.7; LRMS (APCI) m / z calcd for C 24 H 17 F3NO2[M+H] + : 408.11; found: 408.51.

[0141] Example 24: Preparation of Compound 24 In Example 21-2, an indolizine derivative compound (25.4 mg, 92.2% yield) was produced in the same manner as in Example 21, except that 4-methoxyphenylboronic acid (28.7 mg, 0.189 mmol), tetrakis(triphenylphosphine)palladium (15.0 mg, 0.013 mmol) and sodium carbonate (33.6 mg, 0.315 mmol) were added to a solution containing IF-B (30.0 mg, 0.063 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0142] The physical properties of compound 24 prepared in Example 24 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.92 (d, J = 7.4 Hz, 1H), 8.39 (s, 1H), 7.94 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.4 Hz, 2H), 7.49 (m, 3H), 7.38 (s, 1H), 7.04 (d, J = 8.8Hz, 1H), 6.78 (s, 1H), 3.88 (s, 3H), 2.66 (s, 3H). 13 C NMR (100 MHz, CDCl3) δ 195.5, 183.7, 159.2, 143.4, 135.2, 133.2, 132.9, 132.4, 129.5, 129.4, 128.5, 126.1, 125.6, 125.5, 125.4, 125.3, 123.3, 122.6, 122.3,119.8,116.2, 115.0, 114.8, 112.2, 56.1, 55.7, 30.1, 26.7; 25 H 19 F3NO3[M+H] + : 438.12; found: 438.09.

[0143] Example 25: Preparation of Compound 25 In Example 21-2, an indolizine derivative compound (26.5 mg, 93.5% yield) was produced in the same manner as in Example 21, except that 4-(dimethylamino)phenylboronic acid (31.2 mg, 0.189 mmol), tetrakis(triphenylphosphine)palladium (15.0 mg, 0.013 mmol) and sodium carbonate (33.6 mg, 0.315 mmol) were added to a solution containing IF-B (30.0 mg, 0.063 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0144] The physical properties of compound 25 prepared in Example 25 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.91 (d, J = 7.6 Hz, 1H), 8.4 3(s, 1H), 7.95 (d, J = 8.0 Hz, 2H), 7.78 (d, J = 8.0 Hz, 2H), 7.46 (m, 3H), 7.36 (s, 1H), 6.85 (d, J = 8.0 Hz, 2H), 3.03 (s, 6H), 2.65(s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.5, 183.6, 150.0, 143.6, 135.2, 133.1, 132.8, 132.1, 129.4, 129.1, 128.4, 125.5 (2), 125.3, 125.0, 123.3, 123.1, 122.6, 121.5, 120.2, 113.1, 112.0, 40.9, 30.1, 26.6; LRMS (APCI) m / z calcd for C 26 H 22 N2O2[M+H] + : 451.16; found: 451.65.

[0145] Example 26: Preparation of Compound 26 Example 26-1: Preparation of 1-(3-benzoyl-1-bromoindolizin-7-yl)ethanone (IH-B) [ka]

[0146] IH-E : The product was synthesized as in Reaction Scheme 1-6. Specifically, 4-acetylpyridine (105.9 μL, 0.957 mmol) and 2-bromoacetophenone (200.0 mg, 1.01 mmol) were added to DMF (4.0 mL) at 80° C. for 5 hours, and then ethyl acrylate (51.8 μL, 0.479 mmol), copper (II) acetate monohydrate (573.2 mg, 2.87 mmol) and sodium acetate (314.0 mg, 3.83 mmol) were added and stirred at 100° C. for 5 hours. After completion of the reaction, the reaction was monitored by TLC, and the copper acetate was removed by filtration through a Celite pad, and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted with DCM three times. The organic extracts were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to give compound IH-E (556.5 mg, 77.3% yield) as a yellow solid.

[0147] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ9.83 (dd, J = 7.2, 0.8 Hz, 1H), 8.90(s, 1H), 7.80(m, 3H), 7.54(m, 4H) 4.38(q, 2H), 2.69(s, 3H); 13LRMS (ESI) m / z calcd for C 20 H 17 NO4[M+Na] + : 335.1 ,found : 336.2.

[0148] IH-B To IH-E (200.0 mg, 0.60 mmol) in methanol (4 mL) was added KOH (336.8 mg, 6.0 mmol), and the mixture was stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IH-A as a brown solid. The obtained compound IH-A was used immediately in the next step without further purification. Sodium bicarbonate (131.1 mg, 1.56 mmol) was added to IH-A in DMF (2.0 mL), and NBS (97.9 mg, 0.55 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to obtain compound IH-B (135.2 mg, 76.3% yield) as a yellow solid.

[0149] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.85(d, J = 7.4 Hz, 1H), 8.17(s, 1H), 7.8(d, J = 7.6 Hz, 2H), 7.52(m,5H), 2.71(s, 3H); 13C NMR(100 MHz, CDCl3), δ 195.3, 184.8, 139.5, 135.2, 132.2, 131.9, 129.1, 128.6, 128.3, 127.5, 123.9, 119.2, 112.0, 94.1, 26.7; LRMS (ESI) m / z calcd for C 17 H 12 BrNO2[M+Na] + : 341.0, found : x.

[0150] Example 26-2: Preparation of Compound 26 To a solution of IH-B (30.0 mg, 0.088 mmol) in 10:1 DMF and water, 4-trifluorophenylboronic acid (49.95 mg, 0.26 mmol), tetrakis(triphenylphosphine)palladium (20.28 mg, 0.018 mmol) and sodium carbonate (46.4 mg, 0.44 mmol) were added and stirred at 100 °C for 8 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate40%) to give compound 26 (33.8 mg, 94.3% yield) as a yellow solid. [ka]

[0151] The physical properties of compound 26 prepared in Example 26 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.94 (d, J = 7.6 Hz, 1H), 8.40 (s, 1H), 7.85 (dd, J = 5.6 Hz, 2.4 Hz, 2H), 7.74 (d, J = 8.0 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.60 (t, J = 6.8 Hz, 1H), 7.50 (m, 4H), 2.67 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.3, 185.5, 140.0, 137.8, 134.7, 132.6, 131.8, 129.2, 128.6, 128.4, 126.3, 126.2(3), 125.8, 124.2, 120.1, 119.1, 112.2, 26.7; LRMS (ESI) m / z calcd for C 24 H 17 F3NO2[M+H] + : 408.11; found: 408.10.

[0152] Example 27: Preparation of Compound 27 In Example 26-2, an indolizine derivative compound (32.1 mg, 95.6% yield) was produced in the same manner as in Example 26, except that 4-acetylphenylboronic acid (343.12 mg, 0.26 mmol), tetrakis(triphenylphosphine)palladium (20.28 mg, 0.018 mmol) and sodium carbonate (46.4 mg, 0.44 mmol) were added to a solution containing IH-B (30.0 mg, 0.088 mmol) and mixed with DMF and water in a ratio of 10:1. [ka]

[0153] The physical properties of compound 27 prepared in Example 27 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.93 (d, J = 7.6 Hz, 1H), 8.44 (s, 1H), 8.07 (d, J = 8.0 Hz, 2H), 7.85 (d, J = 7.2 Hz, 2H), 7.67 (d, J = 12.0 Hz, 2H), 7.54 (m, 5H), 2.66 (s, 3H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.4, 195.4, 185.5, 140.0, 138.9, 135.7, 134.8, 132.6, 131.8, 129.4, 129.2, 128.6, 128.1, 125.8, 124.3, 120.4,119.3, 112.2, 27.0, 26.7; LRMS (APCI) m / z calcd for C 25 H 20 NO3[M+H] + : 382.14; found: 382.17.

[0154] Example 28: Preparation of Compound 28 In Example 26-2, an indolizine derivative compound (28.5 mg, 95.4% yield) was produced in the same manner as in Example 26, except that methylboronic acid (32.07 mg, 0.26 mmol), tetrakis(triphenylphosphine)palladium (20.28 mg, 0.018 mmol) and sodium carbonate (46.4 mg, 0.44 mmol) were added to a solution containing IH-B (30.0 mg, 0.088 mmol) and mixed with DMF and water in a ratio of 10:1. [ka]

[0155] The physical properties of compound 28 prepared in Example 28 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.92 (d, J = 7.6 Hz, 1H), 8.42 (s, 1H), 7.84 (dd, J = 8.2 Hz, 1.2 Hz, 2H), 7.60 (d, J = 4.8 Hz, 3H), 7.50(m, 6H), 7.38 (t, J = 7.2 Hz, 1H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 185.5, 140.2, 134.7, 134.1, 132.1, 131.7, 129.3, 129.2, 128.5, 128.3, 127.4, 125.7, 123.9, 121.9, 119.8, 111.8, 26.7; LRMS (APCI) m / z calcd for C 23 H 18 NO2[M+H] + : 340.13; found: 340.22.

[0156] Example 29: Preparation of Compound 29 In Example 26-2, an indolizine derivative compound (30.1 mg, 92.7% yield) was produced in the same manner as in Example 26, except that 4-methoxyphenyl boronic acid (39.97 mg, 0.26 mol), tetrakis(triphenylphosphine)palladium (20.28 mg, 0.018 mmol) and sodium carbonate (46.4 mg, 0.44 mmol) were added to a solution containing IH-B (30.0 mg, 0.088 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0157] The physical properties of compound 29 prepared in Example 29 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.88 (d, J = 7.6 Hz, 1H), 8.36 (s, 1H), 7.84 (dd, J = 8.2 Hz, 1.2 Hz, 2H), 7.50(m, 7H), 7.01 (d, J = 4.0 Hz, 2H), 3.86 (s, 3H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 185.4, 159.1, 140.2, 134.6, 131.8, 131.6, 129.5, 129.2, 128.5, 128.3, 126.4, 125.4, 123.8, 121.8, 121.6, 119.9, 114.8, 111.7, 55.7, 26.7; LRMS (ESI) m / z calcd for C 24 H 20 NO3[M+H] + :370.14; found: 370.15.

[0158] Example 30: Preparation of Compound 30 In Example 26-2, an indolizine derivative compound (32.9 mg, 94.9% yield) was produced in the same manner as in Example 26, except that phenyl(dimethylamino)phenylboronic acid (43.40 mg, 0.26 mmol), tetrakis(triphenylphosphine)palladium (20.28 mg, 0.018 mmol) and sodium carbonate (46.4 mg, 0.44 mmol) were added to a solution containing IH-B (30.0 mg, 0.088 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0159] The physical properties of the compound 30 prepared in Example 30 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.89 (d, J = 7.4 Hz, 1H), 8.42 (s, 1H), 7.86 (dd, J = 8.2 Hz, 1.2Hz, 2H), 7.51 (m, 7H), 6.85 (d = 6.8 Hz, 2H), 3.02 (s, 6H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 185.3, 149.9, 140.4, 134.5, 131.5(2), 129.3, 129.1, 128.5, 128.2, 125.0, 123.8, 122.6, 121.9, 120.3, 113.1, 111.5, 53.8, 40.9, 26.6; LRMS (ESI) m / z calcd for C 25 H 23 N2O2[M+H] + : 383.17; found: 383.20.

[0160] Example 31: Production of Compound 31 Example 31-1: Production of 1-(1-bromo-3-(4-methoxybenzoyl)indolizin-7-yl)ethanone (II-B)

change

[0161] II-E: Synthesized as in Reaction Scheme 1-7. Specifically, 4-acetylpyridine (585.2μL, 5.29mmol) and 2-bromoacetophenone (1.5g, 5.6mmol) in DMF (17.6mL) were stirred at 80℃ for 5 hours, and then ethyl acrylate (286.6μL, 2.65mmol), copper(II) acetate monohydrate (3.17g, 15.87mmol) and sodium acetate (1.74g, 21.16mmol) were added and stirred at 100℃ for 5 hours. After completion of the reaction, monitored by TLC, the copper acetate was removed by filtration through a Celite pad, and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted with DCM three times. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate 40%) to give compound II-E (709.8 mg, 73.3% yield) as a yellow solid.

[0162] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) 9.62 (dd J = 7.4, 0.4 Hz, 1H), 8.76 (s, 1H), 7.74(dd, J = 6.6, 2 Hz, 2 H), 7.69 (s, 1H), 7.39 (dd, J = 7.4, 2 Hz, 1H), 6.92(dd, J = 6.8, 2 Hz, 2H), 4.33(q, J = 7.2 Hz, 2H), 3.82(s,3H), 2.61(s, 3H), 1.362(t, J = 7.2 Hz, 3H); 13 C NMR(100 MHz, CDCl3) 195.6, 184.3, 163.4, 162.8, 137.6, 133.7, 131.9, 131.4, 128.4, 127.5, 123.2, 120.9, 113. 8, 112.5, 109.1, 60.6, 55.6, 26.4, 14.8; LRMS (ESI) m / z calcd for C 21H 19 NO4[M+Na]+ : 365.1 ,found :366.2. II-B: II-E (709.8 mg, 1.94 mmol) in methanol (19 mL) was added with KOH (3.1 g, 77.6 mmol) and stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was filtered, washed with water, and dried in a drying oven to obtain compound II-A as a brown solid.

[0163] The obtained compound II-A was used immediately in the next step without further purification. Sodium bicarbonate (478.9 mg, 5.7 mmol) was added to II-A in DMF (10.0 mL), and NBS (354.9 mg, 2.0 mmol) was added in portions at 0 ° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane = 1:5-ethyl acetate 40%) to obtain compound II-B (462.0 mg, 72.1% yield) as a yellow solid.

[0164] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) 9.73(d, J = 7.2Hz,1 H), 8.12(s, 1H), 7.81(d, J = 8.8 Hz, 2H), 7.42 (m, 1H), 6.99(d, 2H), 3.88(s, 3H), 2.68(s, 3H); 13 C NMR(100 MHz, CDCl3)195.3, 183.7, 162.8, 134.8, 132.0, 131.9, 131.4, 128.1, 126.9, 124.0, 119.3, 113.9, 111.7, 93.9, 55.8, 26.6; LRMS (ESI) m / z calcd for C 18 H 14NO4[M+Na]+ : 372. 2 ,found : 372.1.

[0165] Example 31-2: Preparation of Compound 31 To a solution of II-B (30.0 mg, 0.081 mmol) in 10:1 DMF and water (1.1 mL), 4-trifluorophenylboronic acid (46.2 mg, 0.243 mmol), tetrakis(triphenylphosphine)palladium (18.7 mg, 0.016 mmol) and sodium carbonate (42.9 mg, 0.405 mmol) were added and stirred at 100 °C for 8 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate40%) to give compound 31 (34.4 mg, 97.2% yield) as a yellow solid. [ka]

[0166] The physical properties of compound 31 prepared in Example 31 are as follows. 1 H NMR (400 MHz, CDCl3) δ 9.84 (d, J = 7.4 Hz, 1H), 8.39 (s, 1H), 7.88 (dd, J = 6.8 Hz, 2.0 Hz, 2H), 7.74 (d, J = 8.8 Hz, 2H), 7.69 (d, J = 8.8 Hz, 2H), 7.54 (s, 1H), 7.45 (dd, J = 7.2 Hz, 2.0 Hz, 1H), 7.02(d, J = 6.8 Hz, 2H), 3.91 (s, 3H), 2.67 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 195.6, 184.5, 162.8, 137.9, 134.3, 132.4, 132.2, 131.5, 128.4, 126.3, 126.2, 125.3, 124.3, 119.9, 119.3, 114.0, 111.9, 55.9, 26.8; LRMS (ESI) m / z calcd for C 25 H 19 F3NO3[M+H] + : 438.12; found: 438.15.

[0167] Example 32: Preparation of Compound 32 In Example 31-2, an indolizine derivative compound (32.5 mg, 97.5% yield) was produced in the same manner as in Example 31, except that 4-acetylphenylboronic acid (39.8 mg, 0.243 mmol), tetrakis(triphenylphosphine)palladium (18.7 mg, 0.016 mmol) and sodium carbonate (42.9 mg, 0.405 mmol) were added to a solution (1.1 mL) containing II-B (30.0 mg, 0.081 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0168] The physical properties of compound 32 prepared in Example 32 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.84 (d, J = 7.2 Hz, 1H), 8.43 (s, 1H), 8.07 (d, J = 8.0 Hz, 2H), 7.88 (dd, J = 7.0 Hz, 2.0 Hz, 2 H), 7.68 (d, J = 8.4 Hz, 2H), 7.56 (s, 1H), 7.45 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 7.02(dd, J = 6.8 Hz, 1.6 Hz, 2H), 3.90 (s, 3H), 2.65(s, 6H); 13C NMR (100 MHz, CDCl3) δ 197.4, 195.5, 184.5, 162.8, 139.1, 135.6, 134.3, 132.4, 132.3, 131.5, 129.4, 128.4, 128.1, 125.2, 124.4, 120.1, 119.4, 114.0, 111.9, 55.8, 30.1, 27.0, 26.7; LRMS (ESI) m / z calcd for C 26 H 22 NO4[M+H] + found: 412.15.

[0169] Example 33: Preparation of Compound 33 In Example 31-2, an indolizine derivative compound (28.9 mg, 96.6% yield) was produced in the same manner as in Example 31, except that benzene boronic acid (29.6 mg, 0.243 mmol), tetrakis(triphenylphosphine)palladium (18.7 mg, 0.016 mmol) and sodium carbonate (42.9 mg, 0.405 mmol) were added to a solution (1.1 mL) containing II-B (30.0 mg, 0.081 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0170] The physical properties of compound 33 prepared in Example 33 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.84 (d, J = 7.2 Hz, 1H), 8.42 (s, 1H), 7.89 (dd, J = 6.8 Hz, 1.6 Hz, 2H), 7.60 (dd, J = 8.2 Hz, 1.6 Hz, 2H), 7.50 (t, J = 8.0 Hz, 3H), 7.43 (dd, J = 7.6 Hz, 2.0 Hz, 1H), 7.38 (t, J = 7.2 Hz, 1H), 7.01(dd, J = 6.8 Hz, 2.0 Hz, 2H), 3.90 (s, 3H), 2.64 (s, 3H). 13 C NMR (100 MHz, CDCl3) δ 195.6, 184.4, 162.6, 134.2(2), 132.7, 131.8, 131.5, 129.3, 128.3, 128.2, 127.4, 125.1, 124.1, 121.7, 119.9, 113.9, 111.5, 55.8, 26.7; LRMS (ESI) m / z calcd for C 24 H 20 NO3[M+H] + : 370.14; found: 370.15.

[0171] Example 34: Preparation of Compound 34 In Example 31-2, an indolizine derivative compound (30.4 mg, 94.0% yield) was produced in the same manner as in Example 31, except that 4-methoxyphenylboronic acid (36.9 mg, 0.243 mmol), tetrakis(triphenylphosphine)palladium (18.7 mg, 0.016 mmol) and sodium carbonate (42.9 mg, 0.405 mmol) were added to a solution (1.1 mL) containing II-B (30.0 mg, 0.081 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0172] The physical properties of compound 34 prepared in Example 34 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.81 (d, J = 7.2 Hz, 1H), 8.36 (s, 1H), 7.87 (d, J = 7.4 Hz, 2.8 Hz, 2 H), 7.49 (dd, J = 6.6 Hz, 2.0 Hz, 2H), 7.45(s, 1H), 7.40 (dd, J = 7.2 Hz, 2.0 Hz, 1H), 7.02 (m, 4H), 3.90(s, 3H), 3.87 (s, 3H), 2.63 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 184.4, 162.6, 159.0, 134.2, 132.7, 131.5, 129.5, 128.1, 126.6, 124.8, 124.0, 121.6, 119.9, 114.8, 113.8, 111.4, 55.8, 55.7, 30.1, 26.6. LRMS (ESI) m / z calcd for C 25 H 22 NO4[M+H] + found: 400.15.

[0173] Example 35: Preparation of Compound 35 In Example 31-2, an indolizine derivative compound (31.2 mg, 93.3% yield) was produced in the same manner as in Example 31, except that 4-dimethylaminophenylboronic acid (40.0 mg, 0.24 mmol), tetrakis(triphenylphosphine)palladium (18.7 mg, 0.016 mmol) and sodium carbonate (42.9 mg, 0.405 mmol) were added to a solution (1.1 mL) containing II-B (30.0 mg, 0.081 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0174] The physical properties of compound 35 prepared in Example 35 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.80 (d, J = 7.2 Hz, 1H), 8.40 (s, 1H), 7.88 (dd, J = 6.8 Hz, 2.0 Hz, 2H), 7.46 (m, 3H), 7.40 (dd, J = 7.4Hz, 2.0 Hz, 1H), 7.00 (dd, J = 6.6 Hz, 2.0 Hz, 2H), 6.86 (dd, J = 6.8 Hz, 2.0 Hz, 2H), 3.90(s, 3H), 3.02 (s, 6H), 2.63 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.7, 184.4, 162.5, 149.9, 134.1, 132.9, 131.5, 131.2, 129.1, 128.0, 124.5, 124.0, 122.4, 122.1, 120.4, 113.8, 113.2, 111.2, 55.8, 40.9, 26.6; LRMS (ESI) m / z calcd for C 26 H 25 N2O3[M+H] + : 413.18; found: 413.20.

[0175] Example 36: Production of Compound 36 Example 36-1: Production of 1-(1-bromo-3-(4-(diethylamino)benzoyl)indolizin-7-yl)ethanone (IJ-B)

change

[0176] IJ-E: Synthesized as in Reaction Scheme 1-8. Specifically, 4-acetylpyridine (194.9 μL, 1.76 mm) and 2-bromo-4'-diethylaminoacetophenone (500 mg, 1.85 mmol) in DMF (6.0 mL) were stirred at 80° C. for 5 hours, and then ethyl acrylate (88.1 μL, 0.88 mmol), copper (II) acetate monohydrate (1.05 g, 5.28 mmol) and sodium acetate (577.5 mg, 7.04 mmol) were added and stirred at 100° C. for 5 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate 40%) to give compound IJ-E (295.6 mg, 82.7% yield) as a yellow solid.

[0177] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.66(d, J = 7.6 Hz, 1H), 8.89(s, 1H), 7.8(m, 3H), 7.46(dd, J = 7.6Hz, 2Hz, 1H), 6.69(d, J = 7 Hz, 2H), 4.39(q, J = 7.2Hz, 2H), 3.43(q, J = 7.2Hz, 4H), 2.68(s, 3H), 1.42(t, J = 7.2Hz, 3H), 1.21(t, J = 7.2Hz, 6H); 13C NMR(100 MHz, CDCl3), δ 195.9, 183.9, 164.1, 151.0, 137.5, 133.3, 132.3, 132.2, 128.5, 127.1, 125.4, 124.7, 121.6, 121.3, 111.7, 110.5, 108.8, 60.6, 44.9, 26.5, 14.9, 13.0; LRMS (ESI) m / z calcd for C 24 H 26 N2O4[M+Na]+ : 406.2, found : 407.2.

[0178] IJ-B: IJ-E (295.6 mg, 0.73 mmol) in methanol (16 mL) was added with KOH (1.63 g, 29.2 mmol) and stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IJ-A as a brown solid.

[0179] The obtained compound IJ-A was used immediately in the next step without further purification. Sodium bicarbonate (306.6 mg, 3.65 mmol) was added to IJ-A in DMF (10.0 mL), and NBS (136.4 mg, 0.77 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to obtain compound IJ-B (241.0 mg, 80.1% yield) as a yellow solid.

[0180] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3), δ 9.61(d, J = 7.2 Hz, 1H), 8.06(s, 1H), 7.77(d, J = 8.8 Hz, 2H), 7.42(s, 1H), 7.32(dd, J = 2 Hz, 7.4 Hz), 6.66(d, J = 8.8 Hz, 2H), 3.42(q, 7.2 Hz, 4H), 2.64(s, 3H), 1.21(t, J = 7.2 Hz, 6H); 13 C NMR(100 MHz, CDCl3), δ 195.4, 183.1, 150.9, 133.9, 132.1, 131.0, 127.8, 125.9, 125.6, 124.6, 119.4, 111.0, 110.5, 93.4, 77.7, 77.4, 77.1, 44.9, 26.6, 13.0; LRMS (ESI) m / z calcd for C21H21BrN2O2 [M+Na]+ : 412.08 ,found : x.

[0181] Example 36-2: Preparation of Compound 36 To a solution (1.1 mL) of IJ-B (20.0 mg, 0.048 mmol) in 10:1 DMF and water, 4-trifluorophenylboronic acid (27.3 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (11.1 mg, 0.01 mmol) and sodium carbonate (25.4 mg, 0.24 mmol) were added and stirred at 100° C. for 8 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate40%) to give compound 36 (22.2 mg, 96.6% yield) as a yellow solid. [ka]

[0182] The physical properties of compound 36 prepared in Example 36 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.75 (d, J = 7.6 Hz, 1H), 8.39 (s, 1H), 7.87 (d, J = 7.2 Hz, 2H), 7.73 (q, J = 8.8 Hz, 4H), 7.59 (s, 1H), 7.40 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 6.72 (d, J = 9.2 Hz, 2H), 3.46 (q, J = 7.2 Hz, 4H), 2.65 (s, 3H), 1.24 (t, J = 8.0 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 183.9, 150.9, 138.3, 133.5, 132.2, 131.5, 128.3, 128.2, 126.2, 126.0, 125.0, 124.3, 119.5, 119.4, 111.3, 110.5, 44.9, 26.7, 13.0; LRMS (APCI) m / z calcd for C 28 H 26 F3N2O2[M+H] + : 479.19; found: 479.30.

[0183] Example 37: Preparation of Compound 37 In Example 36-2, an indolizine derivative compound (20.5 mg, 94.5% yield) was produced in the same manner as in Example 36, except that 4-acetylphenylboronic acid (323.6 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (11.1 mg, 0.01 mmol) and sodium carbonate (25.4 mg, 0.24 mmol) were added to a solution (1.1 mL) containing IJ-B (20.0 mg, 0.048 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0184] The physical properties of compound 37 prepared in Example 37 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.74 (d, J = 7.4Hz, 1H), 8.43 (s, 1H), 8.08 (dd, J = 6.4 Hz, 2.0 Hz, 2H), 7.87 (d, J = 8.0 Hz, 2H), 7.70 (dd, J = 6.8 Hz, 1.6 Hz, 2H), 7.61 (s, 1H), 7.39 (dd, J = 7.8 Hz, 1.6 Hz, 1H), 6.72 (d, J = 8.4 Hz, 2H), 3.46 (q, J = 7.2 Hz, 4H), 2.67 (s, 3H), 2.65 (s, 3H), 1.24 (t, J = 7.2 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 197.5, 195.6, 183.9, 150.9, 139.5, 135.4, 133.6, 132.2, 131.5, 129.4, 128.2, 128.0, 126.0, 125.1, 124.3, 119.7, 119.6, 111.3, 110.6, 44.9, 27.0, 26.7, 13.0; LRMS (APCI) m / z calcd for C 29 H 29 N2O3[M+H] + : 453.21; found: 453.15.

[0185] Example 38: Preparation of Compound 38 In Example 36-2, an indolizine derivative compound (18.2 mg, 92.2% yield) was produced in the same manner as in Example 36, except that 4-benzeneboronic acid (23.8 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (11.1 mg, 0.01 mmol) and sodium carbonate (17.6 mg, 0.24 mmol) were added to a solution (1.1 mL) containing IJ-B (20.0 mg, 0.048 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0186] The physical properties of compound 38 prepared in Example 38 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.73 (d, J = 7.4 Hz, 1H), 8.41 (s, 1H), 7.88 (d, J = 8.0 Hz, 2H), 7.60 (d, J = 6.4 Hz, 2H), 7.57 (s, 1H), 7.50(t, J = 6.4 Hz, 2H), 7.37 (d, J = 7.2 Hz, 2H), 6.71 (d, J = 9.2 Hz, 2H), 3.45 (q, J = 6.8 Hz, 4H), 2.63 (s, 3H), 1.24 (t, J = 7.2 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 195.7, 184.0, 150.8, 134.6, 133.4, 132.1, 131.0 129.2, 128.3, 128.0, 127.1, 126.3, 124.7, 124.3, 121.3, 120.0, 110.9, 110.5, 44.9, 26.6, 13.0; LRMS (APCI) m / z calcd for C 27 H 27 N2O2[M+H] + found: 411.20.

[0187] Example 39: Preparation of Compound 39 In Example 36-2, an indolizine derivative compound (19.7 mg, 93.4% yield) was produced in the same manner as in Example 36, except that 4-methoxyphenylboronic acid (21.9 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (11.1 mg, 0.01 mmol) and sodium carbonate (25.4 mg, 0.24 mmol) were added to a solution (1.1 mL) containing IJ-B (20.0 mg, 0.048 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0188] The physical properties of compound 39 prepared in Example 39 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.72(d, J = 7.8 Hz, 1H), 8.36 (s, 1H), 7.87 (dd, J = 7.2 Hz, 2.0 Hz, 2H), 7.52 (dd, J = 6.6 Hz, 2.4 Hz, 3H), 7.35 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 7.04 (dd, J = 6.6 Hz, 2.0 Hz, 2H), 6.71 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H), 3.45 (q, J = 7.2 Hz, 4H), 2.63(s, 3H), 1.23 (t, J = 7.2Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 195.7, 183.9, 158.9, 150.7, 133.3, 132.1, 130.7, 129.5, 127.9, 127.0, 126.4, 124.6, 124.0, 121.2, 120.1, 114.7, 110.8, 110.5, 55.7, 44.9, 26.6, 13.0; LRMS (APCI) m / z calcd for C 28 H 29 N2O3[M+H] + : 441.21; found: 441.15.

[0189] Example 40: Preparation of Compound 40 In Example 36-2, an indolizine derivative compound (20.2 mg, 93.0% yield) was produced in the same manner as in Example 36, except that 4-dimethylaminophenylboronic acid (23.8 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (11.1 mg, 0.01 mmol) and sodium carbonate (25.4 mg, 0.24 mmol) were added to a solution (1.1 mL) containing IJ-B (20.0 mg, 0.048 mmol) and mixed with DMF and water at a ratio of 10:1. [ka]

[0190] The physical properties of compound 40 prepared in Example 40 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.70 (d, J = 7.2 Hz, 1H), 8.39 (s, 1H), 7.87 (d, J = 9.2 Hz, 2H), 7.49 (dd, J = 8.6 Hz, 2.0 Hz, 3H), 7.34 (dd, J = 7.6 Hz, 2.0 Hz, 1H), 6.87 (d, J = 8.8Hz, 2H), 6.70 (d, J = 8.8 Hz, 2H), 3.45 (q, J = 7.6 Hz, 4H), 3.03 (s, 6H), 2.62 (s, 3H), 1.24 (t, J = 6.8Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 195.8, 184.0, 150.7, 149.8, 133.3, 132.2, 130.4, 129.1, 127.8, 126.4, 124.6, 123.8, 122.5, 122.0, 120.6, 113.2, 110.6, 110.5, 44.9, 41.0, 26.5, 13.0; LRMS (ESI) m / z calcd for C 29 H 32 N3O2[M+H] + : 454.24; found: 454.23.

[0191] Example 41: Preparation of Compound 41 Example 41-1: Preparation of (1-bromoindolizin-3-yl)(4-(trifluoromethyl)phenyl)methanone (IK-B) [ka]

[0192] IK-E : The product was synthesized as shown in Reaction Scheme 19. Specifically, pyridine (564 μL, 7 mmol) and 2-bromo-1-[4-(trifluoromethyl)-phenyl]ethan-1-one (1.96 mL, 7.35 mmol) were stirred in DMF (15.0 mL) at 100 ° C overnight, and then ethyl acrylate (372 μL, 3.50 mmol), copper (II) acetate monohydrate (2.09 g, 10.5 mmol) and sodium acetate (1.72 g, 21.0 mmol) were added and stirred at 100 ° C for 16 hours. After completion of the reaction, which was monitored by TLC, the copper acetate was removed by filtration through a Celite pad, and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted with DCM three times. The combined organic extracts were dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1-15% hexane with EtOAc) to give compound IK-E (906 mg, 2.50 mmol, 71.6% yield) as a yellow solid.

[0193] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3), δ 9.98(d, J = 6.8 Hz, 1H), 8.42(d, J = 9.2 Hz, 1H), 7.91(d, J = 8.0 Hz, 2H), 7.78(d, J = 8.4 Hz, 2H), 7.76(s, 1H), 7.50(t, J = 8.0 Hz, 1H), 7.14(d, J = 6.2 Hz, 1H), 4.38(q, J = 7.1 Hz, 2H), 1.40(t, J = 7.1 Hz, 3H); 13 C NMR(100 MHz, CDCl3) δ 183.6, 163.6, 142.9, 140.0, 132.9, 132.6, 129.1, 129.9, 128.9, 128.1, 125.3(3), 125.0, 122.3, 121.9, 121.4, 119.5, 115.6, 106.8, 60.3, 14.7; LRMS (ESI) m / z calcd for C 19 H 14 F3NO3[M+Na] + : 361.1, found : 362.1.

[0194] IK-B : KOH (8.44 g, 150 mmol) was added to methanol (20 mL) containing IK-E (632 mg, 2.50 mmol), and the mixture was stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IK-A as a white solid.

[0195] The obtained compound IK-A was used immediately in the next step without further purification. Sodium bicarbonate (630 mg, 7.50 mmol) was added to IK-A in DMF (10.0 mL), and NBS (667 mg, 3.75 mmol) was added in portions at 0 ° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane = 1:8-ethyl acetate 12%) to obtain compound IK-B (664 mg, 1.80 mmol, 72.1% yield) as a yellow solid.

[0196] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.96 (d, J = 7.2 Hz, 1H), 7.87 (d, J = 7.6 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.64 (d, J = 9.2 Hz, 1H), 7.35 (t, J = 7.8 Hz, 1H), 7.32 (s, 1H), 7.05 (t, J = 7.0 Hz, 1H); 13 C NMR(100 MHz, CDCl3) δ 181.4, 142.9, 136.6, 132.4, 128.8, 128.3, 126.5, 125.4, 125.0, 124.9, 122.2, 121.3, 116.7, 114.6, 89.9;LRMS (ESI) m / z calcd for C 16 H9BrF3NO[M+Na] + : 367.0, found : 368.0.

[0197] Example 41-2: Preparation of Compound 41 To a solution of IK-B (59.0 mg, 0.16 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (122 mg, 0.64 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (68.0 mg, 0.64 mmol) were added and stirred at 100 °C for 1 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 41 (62.1 mg, 0.14 mmol, 89.5% yield) as a yellow solid. [ka]

[0198] The physical properties of compound 41 prepared in Example 41 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.05 (d, J = 6.8 Hz, 1H), 7.93 (d, J = 8.0 Hz, 1H), 7.90 (d, J = 8.8 Hz, 1H), 7.78 (d, J = 8.4 Hz, 2H), 7.68 (q, J = 8.0 Hz, 5H), 7.43 (s, 1H), 7.37 (dt, J = 7.9 Hz, 1.2 Hz, 1H), 7.08 (dt, J = 6.2 Hz, 1.6 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 182.8, 143.6, 138.0, 136.7, 132.7, 132.4, 129.2, 129.0, 128.7, 128.4, 127.8, 126.2, 125.8, 125.8, 125.5, 125.4, 125.3(2), 122.1, 117.3, 116.4, 114.9; LRMS (ESI) m / z calcd for C 23 H14 F6NO [M+H] + : 434.35; found: 434.15.

[0199] Example 42: Preparation of Compound 42 In Example 41-2, 4-acetylphenylboronic acid (104 mg, 0.64 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (67.5 mg, 0.64 mmol) were added to a solution containing IK-B (58.6 mg, 0.16 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 7 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (58.4 mg, 0.14 mmol, 89.5% yield) was produced in the same manner as in Example 41. [ka]

[0200] The physical properties of compound 42 prepared in Example 42 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.03 (d, J = 7.2 Hz, 1H), 7.93 (d, J = 8.0 Hz, 2H), 7.84 (d, J = 9.2 Hz, 1H), 7.77 (d, J = 8.0 Hz, 2H), 7.46 (d, J = 8.8 Hz, 2H), 7.34 (s, 1H), 7.27 (dt, J = 7.8 Hz, 0.8 Hz, 1H), 7.00 (d, J = 8.8 Hz, 3H), 3.86 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 182.3, 158.5, 144.0, 136.8, 132.4, 132.0, 129.0(2), 126.6, 125.3, 125.2(2), 125.1(2), 124.9, 122.5, 121.5, 118.0, 117.6, 114.5, 114.3, 55.4; LRMS (ESI) m / z calcd for C 24 H 17 F3NO2[M+H] + : 408.11; found: 408.23.

[0201] Example 43: Preparation of Compound 43 In Example 41-2, an indolizine derivative compound (53.1 mg, 0.14 mmol, 100% yield) was produced in the same manner as in Example 41, except that phenylboronic acid (71.2 mg, 0.57 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (61.0 mg, 0.57 mmol) were added to a solution containing IK-B (53.0 mg, 0.14 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 9 hours. [ka]

[0202] The physical properties of compound 43 prepared in Example 43 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.04 (d, J = 6.8 Hz, 1H), 7.92 (t, J = 8.0 Hz, 2H), 7.76 (d, J = 8.0 Hz, 2H), 7.55 (d, J = 7.6 Hz, 3H), 7.45 (t, J = 7.8 Hz, 2H), 7.39 (s, 1H), 7.32 (m, 2H), 7.04 (dt, J = 6.9 Hz, 1.2 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 182.5, 143.9, 136.8, 134.2, 132.5, 132.1, 129.1, 129.0, 128.9, 127.8, 126.7, 125.6, 125.3, 125.2, 122.5, 121.7, 118.2, 117.6, 114.6; LRMS (ESI) m / z calcd for C 22 H 15 F3NO [M+H] + : 366.10; found: 366.24.

[0203] Example 44: Preparation of Compound 44 In Example 41-2, an indolizine derivative compound (65.9 mg, 0.16 mmol, 100% yield) was produced in the same manner as in Example 41, except that 4-methoxyphenylboronic acid (92.8 mg, 0.61 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (64.7 mg, 0.61 mmol) were added to a solution containing IK-B (56.2 mg, 0.15 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 10 hours. [ka]

[0204] The physical properties of compound 44 prepared in Example 44 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.99 (d, J = 7.2 Hz, 1H), 7.99 (d, J = 8.4 Hz, 2H), 7.88 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.4 Hz, 1H), 7.60 (d, J = 8.0 Hz, 2H), 7.42 (s, 1H), 7.32 (t, J = 8.0 Hz, 1H), 7.01 (t, J = 6.8 Hz, 1H), 2.60 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 197.1, 182.6, 144.0, 143.5, 139.1, 136.7, 136.3, 135.0, 132.6, 132.2, 129.1, 128.9, 128.8, 127.4, 127.2, 126.2, 125.2, 122.4, 122.1, 117.4, 116.6, 114.9, 26.7; LRMS (ESI) m / z calcd for C 23 H 17 F3NO2[M+H] + : 396.11; found: 395.98.

[0205] Example 45: Preparation of Compound 45 In Example 41-2, an indolizine derivative compound (59.5 mg, 0.14 mmol, 91% yield) was produced in the same manner as in Example 41, except that 4-(dimethylamino)phenylboronic acid (108.6 mg, 0.66 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (69.7 mg, 0.66 mmol) were added to a solution containing IK-B (60.6 mg, 0.16 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 11 hours. [ka]

[0206] The physical properties of compound 45 prepared in Example 45 are as follows: 1H NMR (400 MHz, CDCl3) δ 10.03 (d, J = 6.8 Hz, 1H), 7.92 (d, J = 8.0 Hz, 2H), 7.87 (d, J = 8.4 Hz, 1H), 7.75 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.8 Hz, 2H), 7.31 (s, 1H), 7.27 (t, J = 7.2 Hz, 1H), 7.00 (dt, J = 6.9 Hz, 1.6 Hz, 1H), 6.82 (d, J = 8.8 Hz, 2H), 2.98 (s, 6H); 13 C NMR (100 MHz, CDCl3) δ 181.7, 149.1,143.8, 136.5, 131.9, 131.6, 128.8, 128.6, 128.3, 124.9, 124.8, 124.7, 124.3, 122.2, 121.8, 121.1, 118.4, 117.5, 114.1, 112.5, 40.3; LRMS (ESI) m / z calcd for C 24 H 20 F3N2O [M+H] + : 409.14; found: 409.15.

[0207] Example 46: Production of Compound 46 Example 46-1: Production of (1-bromoindolizin-3-yl)(phenyl)methanone (IM-B)

change

[0208] IM-E: The product was synthesized as shown in Reaction Scheme 10. Specifically, pyridine (564μL, 7.00mmol) and bromoacetophenone (1.46g, 7.35mmol) in DMF (15.0mL) were stirred at 100℃ overnight, and then ethyl acrylate (373μL, 3.50mmol), copper(II) acetate monohydrate (2.09g, 10.5mmol) and sodium acetate (1.72g, 21.0mmol) were added and stirred at 100℃ for 16 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water and the organic material was extracted with DCM three times. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1–15% hexane with EtOAc) to give compound IM-E (616 mg, 2.10 mmol, 60% yield) as a yellow solid.

[0209] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.83(d, J = 7.2 Hz, 1H), 8.25(d, J = 9.0 Hz, 1H), 7.73(d, J = 7.2 Hz, 2H), 7.71(s, 1H), 7.46(d, J = 7.2 Hz, 1H), 7.40(t, J = 7.2 Hz, 2H), 7.29(t, J = 8.0 Hz, 1H), 6.93(t, J = 7.0 Hz, 1H), 4.29(q, J = 7.0 Hz, 2H), 1.31(t, J = 7.0 Hz, 3H); 13 C NMR(100 MHz, CDCl3) δ 184.8, 163.4, 139.5, 139.3, 131.1, 128.7, 128.6, 128.4, 128.0, 127.2, 122.1, 121.2, 119.0, 114.9, 105.9, 59.9, 14.5; LRMS (ESI) m / z calcd for C 18 H 15NO3[M+Na] + : 293.1, found : 294.2.

[0210] IM-B IM-E (616 mg, 2.10 mmol) in methanol (20 mL) was added with KOH (7.06 g, 126 mmol) and stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IM-A as a white solid.

[0211] The obtained compound IM-A was used immediately in the next step without further purification. Sodium bicarbonate (529 mg, 6.30 mmol) was added to DMF (10.0 mL) containing IM-A, and NBS (561 mg, 3.15 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IM-B (590 mg, 1.96 mmol, 93.6% yield) as a yellow solid.

[0212] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 10.04 (d, J = 6.8 Hz, 1H), 7.78 (d, J = 6.4 Hz, 2H), 7.61 (d, J = 8.8 Hz, 1H), 7.54 (d, J = 7.6 Hz, 1H), 7.50 (d, J =7.6 Hz, 2H), 7.37 (s, 1H), 7.30 (m, 1H), 6.98 (t, J = 7.0 Hz, 1H); 13C NMR(100 MHz, CDCl3) δ 184.0, 140.3, 136.9, 131.3, 129.0, 128.8, 128.5, 127.2, 125.4, 122.3, 117.3, 114.8, 89.9, 47.1, 34.8; LRMS (ESI) m / z calcd for C 15 H 10 BrNO [M+Na] + : 299.0, found : 300.0.

[0213] Example 46-2: Preparation of Compound 46 To a solution of IM-B (59.4 mg, 0.19 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (150 mg, 0.79 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (84.0 mg, 0.79 mmol) were added and stirred at 100 °C for 9 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 46 (33.9 mg, 0.09 mmol, 46.8% yield) as a yellow solid. [ka]

[0214] The physical properties of compound 46 prepared in Example 46 are as follows: 1H NMR (400 MHz, CDCl3) δ 10.04 (d, J = 6.8 Hz, 1H), 7.88 (d, J = 8.8 Hz, 1H), 7.84 (m, J = 6.8 Hz, 2H), 7.67 (m, J = 2.4 Hz, 4H), 7.56 (d, J = 7.2 Hz, 1H), 7.52 (d, J = 7.2 Hz, 2H), 7.49 (s, 1H), 7.31 (dt, J = 7.9 Hz, 1.2 Hz, 1H), 7.03 (dt, J = 6.9 Hz, 1.6 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 184.5, 140.4, 138.3, 136.1, 131.0, 129.0, 128.8, 128.7, 128.4, 128.2, 128.0, 127.7, 125.7, 125.7, 125.7, 125.6, 125.4, 122.9, 122.4, 117.1, 115.8, 114.4; LRMS (ESI) m / z calcd for C 22 H 15 F3NO [M+H] + found: 366.10.

[0215] Example 47: Preparation of Compound 47 In Example 46-2, 4-acetylphenylboronic acid (121 mg, 0.74 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (78.7 mg, 0.74 mmol) were added to a solution containing IM-B (55.5 mg, 0.18 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 12 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:2.5-ethyl acetate40%), but an indolizine derivative compound (50.0 mg, 0.14 mmol, 79.2% yield) was produced in the same manner as in Example 46. [ka]

[0216] The physical properties of compound 47 prepared in Example 47 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.02 (d, J = 6.8 Hz, 1H), 8.02 (d, J = 7.2 Hz, 2H), 7.89 (d, J = 8.8 Hz, 1H), 7.84 (d, J = 6.8 Hz, 2H), 7.69 (d, J = 7.6 Hz, 1H), 7.63 (d, J = 7.6 Hz, 2H), 7.56 (d, J = 7.2 Hz, 1H), 7.53 (s, 1H), 7.51 (s, 1H), 7.29 (t, J = 7.0 Hz, 1H), 7.00 (t, J = 6.6 Hz, 1H), 2.63 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.0, 184.3, 143.9, 140.3, 139.4, 136.2, 136.1, 134.6, 130.9, 128.9, 128.8, 128.7, 128.1, 127.2, 127.1, 125.6, 125.3, 122.4, 117.2, 115.9, 114.4, 26.7, 26.6; LRMS (ESI) m / z calcd for C 23 H 18 NO2[M+H] + : 340.13; found:340.27.

[0217] Example 48: Preparation of Compound 48 In Example 46-2, an indolizine derivative compound (56.2 mg, 0.18 mmol, 89.9% yield) was produced in the same manner as in Example 46, except that phenylboronic acid (100 mg, 0.82 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (87.0 mg, 0.82 mmol) were added to a solution containing IM-B (61.5 mg, 0.21 mmol) and mixed with DMF and water in a 2:1 ratio. [ka]

[0218] The physical properties of compound 48 prepared in Example 48 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.04 (d, J = 6.8 Hz, 1H), 7.89 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 6.8 Hz, 2H), 7.19 (m, 7H), 7.31 (t, J = 7.4 Hz, 1H), 7.27 (d, J = 6.6 Hz, 1H), 7.25 (d, J = 6.6 Hz, 1H), 6.99 (t, J = 6.6 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 183.9, 140.3, 135.9, 134.2, 130.4, 128.5, 128.4, 127.8, 127.5, 126.1, 125.0, 124.6, 121.8, 117.2, 117.1, 113.8; LRMS (ESI) m / z calcd for C 21 H 16 NO [M+H] + : 298.12; found: 298.10.

[0219] Example 49: Preparation of Compound 49 In Example 46-2, an indolizine derivative compound (51.4 mg, 0.15 mmol, 74.7% yield) was produced in the same manner as in Example 46, except that 4-methoxyphenylboronic acid (129 mg, 0.83 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (88.0 mg, 0.83 mmol) were added to a solution containing IM-B (62.0 mg, 0.21 mmol) and mixed with DMF and water in a 2:1 ratio. [ka]

[0220] The physical properties of compound 49 prepared in Example 49 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.03 (d, J = 6.8 Hz, 1H), 7.84 (s, 1H), 7.82 (m, 2H), 7.53 (d, J = 6.8 Hz, 1H), 7.50 (s, 1H), 7.48 (m, 4H), 7.40 (s, 1H), 7.23 (m, 1H), 6.99 (d, J = 8.8 Hz, 2H), 3.85 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 184.1, 158.3, 140.7, 136.2, 130.7, 128.9, 128.8, 128.8, 128.1, 127.0, 125.0, 124.7, 121.9, 121.3, 117.5, 117.4, 114.2, 114.0, 55.4; LRMS (ESI) m / z calcd for C 22 H 18 NO2[M+H] + : 328.13; found: 328.10.

[0221] Example 50: Preparation of Compound 50 In Example 46-2, an indolizine derivative compound (67.0 mg, 0.19 mmol, 87% yield) was produced in the same manner as in Example 46, except that 4-(dimethylamino)phenylboronic acid (149 mg, 0.90 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (95.7 mg, 0.90 mmol) were added to a solution containing IM-B (27.5 mg, 0.11 mmol) and mixed with DMF and water in a 2:1 ratio, and the mixture was stirred at 100° C. for 11 hours. [ka]

[0222] The physical properties of compound 50 prepared in Example 50 are as follows: 1 H NMR (400 MHz, CDCl3) δ 10.02 (d, J = 7.6 Hz, 1H), 7.87 (s, 1H), 7.84 (d, J = 6.4 Hz, 2H), 7.53 (d, J = 7.6 Hz, 1H), 7.49 (d, J = 7.6 Hz, 2H), 7.43 (d, J = 8.8 Hz, 2H), 7.39 (s, 1H), 7.21 (dt, J = 7.8 Hz, 1.2 Hz, 1H), 6.95 (dt, J = 7.0 Hz, 1.2 Hz, 1H), 6.82 (d, J = 8.8 Hz, 2H), 2.99 (s, 6H); 13 C NMR (100 MHz, CDCl3) δ 183.9, 149.3, 140.9, 136.2, 130.6, 128.8, 128.7, 128.6, 128.0, 124.7, 124.3, 122.5, 121.8, 121.3, 118.1, 117.7, 113.9, 112.8, 40.7; LRMS (ESI) m / z calcd for C 23 H 21 NO [M+H] + : 341.16; found: 341.15.

[0223] Example 51: Preparation of Compound 51 Example 51-1: Preparation of (1-bromoindolizin-3-yl)(4-methoxyphenyl)methanone (IN-B) [ka]

[0224] IN-E: The product was synthesized as in Reaction Scheme 1-11. Specifically, pyridine (483 μL, 6.00 mmol) and 2-bromo-4-methoxyacetophenone (1.44 g, 6.30 mmol) were added to DMF (10.0 mL) at 100° C. overnight, and then ethyl acrylate (320 μL, 3.00 mmol), copper (II) acetate monohydrate (1.79 g, 9.00 mmol) and sodium acetate (1.47 g, 18.0 mmol) were added and stirred at 100° C. for 16 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and then concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1–15% hexane with EtOAc) to give compound IN-E (467 mg, 1.44 mmol, 48.2% yield) as a yellow solid.

[0225] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.90(d, J = 6.8 Hz, 1H), 8.38(d, J = 8.8 Hz, 1H), 7.85(s, 1H), 7.83(d, J = 3.2 Hz, 2H), 7.42(q, J = 9.0 Hz, 1H), 6.97(t, J = 7.0 Hz, 1H), 7.01(d, J = 8.8 Hz, 2H), 4.38(q, J = 7.1 Hz, 2H), 3.90(s, 3H), 1.40(t, J = 7.0 Hz, 3H); 13 C NMR(100 MHz, CDCl3) δ 183.6, 163.6, 162.2, 139.2, 132.1, 131.0, 128.7, 127.6, 127.0, 122.3, 121.6, 119.0, 114.7, 113.5, 105.7, 60.0, 55.4, 14.7; LRMS (ESI) m / z calcd for C 19 H17 NO4[M+Na] + : 323.1, found : 324.2.

[0226] IN-B : KOH (4.84 g, 86.4 mmol) was added to IN-E (467 mg, 1.44 mmol) in methanol (10 mL) and stirred at room temperature for 14 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IN-A as a white solid.

[0227] The obtained compound IN-A was used immediately in the next step without further purification. Sodium bicarbonate (363 mg, 4.32 mmol) was added to IN-A in DMF (5.0 mL), and NBS (384 mg, 2.16 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IN-B (350 mg, 1.06 mmol, 73.6% yield) as a yellow solid.

[0228] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.83 (d, J = 6.8 Hz, 1H), 7.77 (d, J = 8.8 Hz, 2H), 7.51 (d, J = 8.8 Hz, 1H), 7.34 (s, 1H), 7.18 (q, J = 8.8 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 6.89 (t, J = 6.8 Hz, 1H), 3.84 (s, 3H); 13C NMR(100 MHz, CDCl3) δ 184.0, 164.1, 162.2, 139.3, 132.0, 130.9, 128.7, 127.9, 127.1, 122.3, 119.1, 114.8, 113.4, 105.3, 55.4, 51.2.

[0229] Example 51-2: Preparation of Compound 51 To a solution of IN-B (50.2 mg, 0.15 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (115 mg, 0.60 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (64.4 mg, 0.60 mmol) were added and stirred at 100 °C for 12 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 51 (48.2 mg, 0.12 mmol, 80.2% yield). [ka]

[0230] The physical properties of compound 51 prepared in Example 51 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.96 (d, J = 6.8 Hz, 1H), 7.85 (dd, J = 7.0 Hz, 1.6 Hz, 3H), 7.67 (d, J = 2.0 Hz, 3H), 7.51 (s, 1H), 7.28 (t, J = 7.6 Hz, 1H), 7.01 (d, J = 8.8 Hz, 2H), 6.98 (d, J = 6.8 Hz, 1H), 6.93 (d, J = 8.4 Hz, 1H); 13C NMR (100 MHz, CDCl3) δ 183.8, 162.1, 138.4, 136.1, 132.8, 131.1, 129.0, 128.4, 128.1, 127.8, 126.9, 125.8(2), 125.6, 125.4, 125.1, 122.6, 117.2, 115.7, 115.6, 114.4, 113.6, 55.6; LRMS (ESI) m / z calcd for C 23 H 17 F3NO2[M+H] + : 396.11; found: 396.10.

[0231] Example 52: Preparation of Compound 52 In Example 51-2, 4-acetylphenylboronic acid (42 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (27 mg, 0.25 mmol) were added to a solution containing IN-B (21 mg, 0.06 mmol) and mixed with DMF and water in a ratio of 2:1, and the concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (22.6 mg, 0.06 mmol, 97.1% yield) was produced in the same manner as in Example 51. [ka]

[0232] The physical properties of compound 52 prepared in Example 52 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.96 (d, J = 7.2 Hz, 1H), 8.03 (d, J = 8.4 Hz, 2H), 7.90 (d, J = 9.2 Hz, 2H), 7.86 (d, J = 8.4 Hz, 2H), 7.66 (d, J = 8.0 Hz, 2H), 7.54 (s, 1H), 7.28 (t, J = 7.8 Hz, 1H), 7.02 (d, J = 8.4 Hz, 2H), 3.90 (s, 3H), 2.64 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.1, 183.4, 161.8, 139.4, 135.7, 134.4, 132.5, 130.7, 128.7, 127.1, 125.1, 124.7, 122.4, 177.0, 115.5, 114.0, 113.3, 55.3, 26.4; LRMS (ESI) m / z calcd for C 24 H 20 NO3[M+H] + : 370.14; found:370.15.

[0233] Example 53: Preparation of Compound 53 In Example 51-2, an indolizine derivative compound (21.8 mg, 0.06 mmol, 100% yield) was produced in the same manner as in Example 51, except that phenylboronic acid (29.0 mg, 0.24 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (26.0 mg, 0.24 mmol) were added to a solution containing IN-B (20.0 mg, 0.06 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 13 hours. [ka]

[0234] The physical properties of compound 53 prepared in Example 53 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.97 (d, J = 6.8 Hz, 1H), 7.87 (d, J = 6.4 Hz, 2H), 7.57 (d, J = 8.0 Hz, 2H), 7.49 (s, 1H), 7.44 (d, J = 7.6 Hz, 2H), 7.31 (t, J = 7.4 Hz, 1H), 7.21 (t, J = 7.6 Hz, 1H), 7.0 (d, J = 8.4 Hz, 2H), 6.92 (t, J = 6.9 Hz, 1H), 6.89 (t, J = 6.8 Hz, 1H), 3.89 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 183.5, 161.9, 136.0, 134.7, 133.2, 131.0, 128.8, 127.9, 126.4, 126.6, 124.9, 124.6, 123.9, 122.2, 118.6, 117.5, 117.3, 115.4, 114.0, 113.5, 102.3, 55.6; LRMS (ESI) m / z calcd for C 22 H 18 NO2[M+H] + : 328.13; found:328.15.

[0235] Example 54: Preparation of Compound 54 In Example 51-2, an indolizine derivative compound (22.6 mg, 0.06 mmol, 100% yield) was produced in the same manner as in Example 51, except that 4-methoxyphenylboronic acid (38.0 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (26.7 mg, 0.25 mmol) were added to a solution containing IN-B (20.8 mg, 0.06 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 13 hours. [ka]

[0236] The physical properties of compound 54 prepared in Example 54 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.96 (d, J = 7.2 Hz, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.81 (d, J = 7.6 Hz, 1H), 7.48 (d, J = 8.8 Hz, 2H), 7.42 (s, 1H), 7.19 (dt, J = 7.7 Hz, 1.2 Hz, 1H), 7.00 (d, J = 2.4 Hz, 2H), 6.98 (d, J = 2.4 Hz, 2H), 6.94 (dt, J = 6.4 Hz, 1.2 Hz, 1H), 3.89 (s, 3H), 3.85 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 183.7, 162.1, 158.6, 136.2, 133.6, 131.3, 129.3, 129.1, 127.5, 124.9, 124.7, 122.4, 117.8, 117.4, 114.6, 114.2, 113.8, 55.9, 55.8; LRMS (ESI) m / z calcd for C 23 H 20 NO3[M+H] + : 358.14; found: 358.10.

[0237] Example 55: Preparation of Compound 55 In Example 51-2, an indolizine derivative compound (23.8 mg, 0.06 mmol, 100% yield) was produced in the same manner as in Example 51, except that 4-(dimethylamino)phenylboronic acid (40.0 mg, 0.24 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (26.0 mg, 0.24 mmol) were added to a solution containing IN-B (20.0 mg, 0.06 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 13 hours. [ka]

[0238] The physical properties of compound 55 prepared in Example 55 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.96 (d, J = 7.2 Hz, 1H), 7.86 (d, J = 8.8 Hz, 3H), 7.44 (d, J = 6.8 Hz, 2H), 7.41 (s, 1H), 7.17 (dt, J = 8.8 Hz, 1.2 Hz, 1H), 6.99 (d, J = 8.8 Hz, 2H), 6.92 (dt, J = 6.9 Hz, 1.6 Hz, 1H), 6.83 (d, J = 8.8 Hz, 2H), 3.89 (s, 3H), 2.99 (s, 6H); 13 C NMR (100 MHz, CDCl3) δ 183.3, 161.8, 149.3, 136.0, 133.5, 131.1, 128.7(2), 124.4, 124.0, 122.9, 117.8, 113.8, 113.5, 113.0, 55.6, 40.9; LRMS (ESI) m / z calcd for C 24 H 23 N2O2[M+H] + : 371.17; found: 371.15.

[0239] Example 56: Preparation of Compound 56 Example 56-1: Preparation of (1-bromoindolizin-3-yl)(4-(diethylamino)phenyl)methanone (IO-B) [ka]

[0240] IO-E: The product was synthesized as in Reaction Scheme 1-12. Specifically, pyridine (695 μL, 6.00 mmol) and 2-bromo-4'-(diethylamino)acetophenone (1.70 mL, 6.3 mmol) were added to DMF (10.0 mL) and stirred at 100 ° C overnight, and then ethyl acrylate (320 μL, 3.00 mmol), copper (II) acetate monohydrate (1.79 g, 9.00 mmol) and sodium acetate (1.47 g, 18.0 mmol) were added and stirred at 100 ° C for 16 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and then concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1–15% hexane with EtOAc) to give compound IO-E (273 mg, 0.75 mmol, 25.0% yield) as a yellow solid.

[0241] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.94 (d, J = 8.0 Hz, 1H), 8.35 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 6.0 Hz, 1H), 7.86 (s,2H), 7.34 (m, 1H), 6.98 (t, J = 7.6 Hz, 1H), 6.72 (d, J = 9.2 Hz, 2H), 4.41 (q, J = 7.2 Hz, 2H), 3.43 (q, J = 7.1 Hz, 4H), 1.43 (t, J = 7.2 Hz, 3H), 1.22 (t, J = 7.2 Hz, 6H).; 13C NMR(100 MHz, CDCl3) δ 186.8, 156.2, 136.0, 134.4, 129.4, 128.8, 127.8, 126.5, 124.8, 124.4, 124.1, 123.0, 122.1, 120.0, 118.5, 117.5, 117.4, 115.4, 114.3, 113.9, 102.5, 27.1, 27.9; LRMS (ESI) m / z calcd for C 22 H 24 N2O3[M+Na] + : 364.2, found : 365.2. IO-B IO-E (273 mg, 0.74 mmol) in methanol (10 mL) was added with KOH (4.20 g, 74.9 mmol) and stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IO-A as a white solid.

[0242] The obtained compound IO-A was used immediately in the next step without further purification. Sodium bicarbonate (189 mg, 2.24 mmol) was added to IO-A in DMF (5.0 mL), and NBS (200 mg, 1.12 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IO-B (187 mg, 0.50 mmol, 67.3% yield) as a yellow solid.

[0243] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3), δ 9.88 (d, J = 7.2 Hz, 1H), 8.03 (s, 1H), 7.83(s, 1H), 7.69 (dd, J = 8.2 Hz, 1H), 7.60 (d, J = 8.8 Hz, 1H), 7.41 (s, 1H), 7.28 (m, 1H), 7.12 (d, J = 8.4 Hz, 1H), 6.98 (t, J = 7.0 Hz, 1H), 3.25 (q, J = 6.9 Hz, 4H), 1.10 (t, J = 7.0 Hz, 6H); 13 C NMR(100 MHz, CDCl3) δ 181.4, 152.2, 136.6, 135.2, 134.9, 128.6, 126.5, 125.1, 122.6, 122.0, 121.9, 120.5, 117.2, 114.6, 89.7, 46.6, 46.43, 12.8, 12.7.

[0244] Example 56-2: Preparation of Compound 56 To a solution of IO-B (24 mg, 0.06 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (49.0 mg, 0.25 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (27.0 mg, 0.25 mmol) were added and stirred at 100 °C for 12 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 56 (19.0 mg, 0.04 mmol, 72.5% yield) as a yellow solid. [ka]

[0245] The physical properties of compound 56 prepared in Example 56 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.97 (d, J = 7.2 Hz, 1H), 7.86 (d, J = 8.0 Hz, 1H), 7.81 (d, J = 8.4 Hz, 1H), 7.70 (m, 6H), 7.58 (s, 1H), 7.26 (m, 1H), 7.15 (d, J = 8.4 Hz, 1H), 6.98 (dt, J = 6.9 Hz, 1.2 Hz,1H), 2.99 (q, J = 7.0 Hz, 4H), 0.98 (t, J = 7.2 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 183.9, 152.2, 136.3, 134.0, 133.7, 133.1, 130.1, 129.3(2), 129.2, 128.2(2), 126.1(2), 125.7,125.6(2), 123.0, 120.3, 117.5, 115.9, 114.6, 46.2, 30.2, 12.5; LRMS (ESI) m / z calcd for C 26 H 24 F3N2O [M+H] + : 437.18; found: 437.20.

[0246] Example 57: Preparation of Compound 57 In Example 56-2, 4-acetylphenylboronic acid (53.0 mg, 0.32 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (34.0 mg, 0.32 mmol) were added to a solution containing IO-B (30.0 mg, 0.08 mmol) and mixed with DMF and water in a ratio of 2:1, and the concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (18.9 mg, 0.04 mmol, 57.5% yield) was produced in the same manner as in Example 56. [ka]

[0247] The physical properties of compound 57 prepared in Example 57 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 6.8 Hz, 1H), 8.05 (d, J = 7.2 Hz, 3H), 7.90 (s, 1H), 7.71 (d, J = 8.4 Hz, 3H), 7.67 (d, J = 8.4 Hz, 1H), 7.56 (s, 1H), 7.30 (dt, J = 7.4 Hz, 1.2 Hz, 1H), 7.12 (d, J = 8.0 Hz, 1H), 7.00 (m, 1H), 3.27 (q, J = 7.0 Hz, 4H), 2.65 (s, 3H), 1.13 (t, J = 7.0 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 197.1, 182.1, 150.4, 143.9, 139.3, 136.1, 135.9, 134.5, 134.1, 131.5, 128.7, 128.6, 128.4, 127.7, 127.1, 125.3, 124.6, 122.1, 121.4, 117.1, 115.7, 114.1, 45.8, 29.6, 26.6, 12.3; LRMS (ESI) m / z calcd for C 27 H 27 N2O2[M+H] + : 411.20; found: 411.38.

[0248] Example 58: Preparation of Compound 58 In Example 56-2, an indolizine derivative compound (22.2 mg, 0.06 mmol, 75.3% yield) was produced in the same manner as in Example 56, except that phenylboronic acid (39.4 mg, 0.32 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (34.0 mg, 0.32 mmol) were added to a solution containing IO-B (30.0 mg, 0.08 mmol) and mixed with DMF and water in a 2:1 ratio, and the mixture was stirred at 100°C for 13 hours. [ka]

[0249] The physical properties of compound 58 prepared in Example 58 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.98 (d, J = 7.2 Hz, 1H), 7.87 (d, J = 9.2 Hz, 1H), 7.80 (d, J = 7.6 Hz, 1H), 7.59 (t, J = 7.4 Hz, 3H), 7.45 (t, J = 7.6 Hz, 2H), 7.39 (t, J = 7.6 Hz, 2H), 7.30 (d, J = 7.6 Hz, 1H), 7.20 (dt, J = 7.8 Hz, 1.2 Hz, 1H), 7.12 (dd, J = 8.2 Hz, 2.4 Hz, 1H), 6.94 (dt, J = 6.9 Hz, 1.2 Hz, 1H), 3.01 (q, J = 4.4 Hz, 4H), 0.97 (t, J = 7.0 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 183.5, 151.4, 141.1, 135.6, 134.6, 133.0, 132.7, 128.8, 128.5, 128.3, 128.0, 127.6, 126.4, 126.1, 124.5, 124.1, 122.1, 121.1, 119.3, 117.2, 116.8, 113.6, 45.9, 45.5, 12.0; LRMS (ESI) m / z calculation for C25 H 25 NO [M+H] + : 369.19; found: 369.36.

[0250] Example 59: Preparation of Compound 59 In Example 56-2, an indolizine derivative compound (42.5 mg, 0.10 mmol, 100% yield) was produced in the same manner as in Example 56, except that 4-methoxyphenylboronic acid (65.0 mg, 0.42 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (45.0 mg, 0.42 mmol) were added to a solution containing IO-B (39.5 mg, 0.10 mmol) and mixed in a 2:1 ratio of DMF and water, and the mixture was stirred at 100° C. for 13 hours. [ka]

[0251] The physical properties of compound 59 prepared in Example 59 are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 6.8 Hz, 1H), 7.89 (s, 1H), 7.82 (d, J = 8.8 Hz, 1H), 7.70 (dd, J = 8.2 Hz, 2.0 Hz, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.44 (s, 1H), 7.22 (t, J = 7.9 Hz, 1H), 7.11 (d, J = 8.0 Hz, 1H), 7.00 (d, J = 6.8 Hz, 2H), 6.95 (dt, J = 7.2 Hz, 1.2 Hz, 2H), 3.86 (s, 3H), 3.26 (q, J = 7.1 Hz, 4H), 0.96 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 182.2, 158.4, 150.4, 136.3, 135.0, 131.8, 129.7, 129.1, 128.9, 128.0, 127.1, 124.7, 124.6, 121.8(2), 117.6, 117.4, 114.4, 114.1, 113.7, 55.5, 46.7, 45.7, 29.9, 12.6; LRMS (ESI) m / z calcd for C 26 H 27 N2O2[M+H] + : 399.20; found: 399.35.

[0252] Example 60: Preparation of Compound 60 In Example 56-2, an indolizine derivative compound (257.8 mg, 0.14 mmol, 84.6% yield) was produced in the same manner as in Example 56, except that 4-(dimethylamino)phenylboronic acid (109 mg, 0.66 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (70.0 mg, 0.66 mmol) were added to a solution containing IO-B (73.0 mg, 0.16 mmol) and mixed with DMF and water in a 2:1 ratio. [ka]

[0253] The physical properties of compound 60 prepared in Example 60 are as follows: 1H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 6.8 Hz, 1H), 7.89 (d, J = 2.4 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 8.4 Hz, 1H), 7.50 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 8.8 Hz, 2H), 7.43 (s, 1H), 7.20 (dt, J = 7.9 Hz, 1.2 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 6.93 (dt, J = 6.8 Hz, 1.2 Hz, 1H), 6.84 (d, J = 6.8 Hz, 2H), 3.26 (q, J = 7.1 Hz, 4H), 3.00 (s, 6H), 1.12 (t, J = 7.0 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 197.5, 197.2, 183.5, 151.8, 146.4, 139.7, 135.9, 135.4, 134.7, 133.6, 133.1, 132.7, 129.7, 129.0, 128.9, 128.7, 128.5, 127.4, 125.3, 124.7, 122.7, 119.8, 117.3, 115.7, 114.2, 45.8, 26.8, 12.2; 27 H 30 NO [M+H] + : 412.23; found: 412.25.

[0254] Example 61: Preparation of Compound 61 Example 61-1: Preparation of 1-(3-benzoyl-1-bromoindolizin-7-yl)ethanone (IH-B)

[0255] In the same manner as in Example 26-1, 1-(3-benzoyl-1-bromoindolizin-7-yl)ethanone, which is a compound represented by IH-B, was prepared.

[0256] Example 61-2: Preparation of Compound 61 To a solution of IH-B (20.0 mg, 0.06 mmol) in 2:1 DMF and water, 4-pyridylboronic acid (8.9 mg, 0.02 mmol), tetrakis(triphenylphosphine)palladium (9.0 mg, 0.3 mol%) and sodium carbonate (11.0 mg, 0.10 mmol) were added and stirred at 100 °C for 10 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:1-ethyl acetate50%) to give compound 61 (1.5 mg, 16.9% yield) as a yellow solid. [ka]

[0257] The physical properties of compound 61 prepared in Example 61 are as follows: 1 H NMR (600 MHz, CDCl3) δ 9.88 (d, J = 7.5 Hz, 1H), 8.19 (s, 1H), 7.83 (d, J = 7.6 Hz, 2H), 7.71 (dd, J = 12.7, 5.9 Hz, 2H), 7.58 (t, J = 7.4 Hz, 1H), 7.51 (t, J = 7.6 Hz, 2H), 7.45 (dd, J = 7.3, 1.5 Hz, 1H), 7.42 (dd, J = 10.9, 5.9 Hz, 2H), 7.39 (d, J = 7.6 Hz, 2H), 6.81 (d, J = 4.6 Hz, 1H), 2.67 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 195.1, 185.5, 140.3, 131.8, 131.6, 131.3m 129.2, 128.5, 128.3, 125.6, 120.1, 118.5, 114.5, 111.6 105.4, 102.0, 26.4, 17.3, 16.6; LRMS (ESI) m / z calcd for C 22 H 17 N2O2[M+H] + : 341.12; found: 341.2650 Example 62: Preparation of Compound 62 In Example 61, 3-amino-4-methylphenylboronic acid (27.0 mg, 0.18 mmol), tetrakis(triphenylphosphine)palladium (21.0 mg, 0.3 mol%) and sodium carbonate (19.0 mg, 0.18 mmol) were added to a solution containing IH-B (20.7 mg, 0.06 mmol) and a mixture of DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 19 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate20%), and the same procedure as in Example 61 was used to obtain compound 62 (11.6 mg, 52.5% yield) as a yellow solid. [ka]

[0258] The physical properties of compound 62 prepared in Example 62 are as follows: 1 H NMR (600 MHz, CDCl3) δ 9.90 (d, J = 7.5 Hz, 1H), 8.44 (s, 1H), 7.85 (m, 2H), 7.58 (m, 1H), 7.51 (t, J = 7.6 Hz, 2H), 7.46 (dd, J = 7.0, 2.4 Hz, 2H), 7.17 (d, J = 7.6 Hz, 1H), 6.89 (m, 2H), 6.18 (m, 1H), 2.64 (s, 3H), 2.24 (s, 3H);13 C NMR (100 MHz, CDCl3) δ 195.1, 185.5, 140.3, 131.8, 131.6, 131.3m 129.2, 128.5, 128.3, 125.6, 120.1, 118.5, 114.5, 111.6 105.4, 102.0, 26.4, 17.3, 16.6; LRMS (ESI) m / z calcd for C 24 H 21 N2O2[M+H] + : 369.15; found: 369.3428.

[0259] Example 63: Preparation of Compound 63 In Example 61, 4-aminobenzeneboronic acid (25.0 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (19.5 mg, 0.3 mol%) and sodium carbonate (19.4 mg, 0.14 mmol) were added to a solution containing IH-B (17.4 mg, 0.04 mmol) and a mixture of DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 1 hour. The same method as in Example 61 was used to obtain compound 63 (14.1 mg, 82.9% yield) as a yellow solid. [ka]

[0260] The physical properties of compound 63 prepared in Example 63 are as follows: 1 H NMR (600 MHz, CDCl3) δ 9.89 (d, J = 7.5 Hz, 1H), 8.38 (s, 1H), 7.85 (d, J = 7.8 Hz, 2H), 7.56 (m, 1H), 7.51 (t, J = 7.5 Hz, 2H), 7.43 (m, 1H), 7.42 (s, 1H), 7.36 (d, J = 8.2 Hz, 2H), 6.80 (d, J = 8.2 Hz, 2H), 3.80 (s, 2H), 2.63 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 195.7, 185.5, 146.0, 140.3, 134.5, 131.6, 131.5, 129.3, 129.2, 128.4, 128.2, 125.1, 124.1, 123.7, 122.4, 120.0, 115.7, 111.5, 26.3; LRMS (ESI) m / z calcd for C 23 H 19 N2O2[M+H] + : 355.14; found: 355.2327.

[0261] Example 64: Preparation of Compound 64 In Example 61, 4-(diethylamino)benzeneboronic acid (6.8 mg, 0.03 mmol), tetrakis(triphenylphosphine)palladium (12.0 mg, 0.3 mol%) and sodium carbonate (11.2 mg, 0.10 mmol) were added to a solution containing IH-B (10.1 mg, 0.03 mmol) and a mixture of DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 3 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:3-ethyl acetate 25%), and the same procedure as in Example 61 was used to obtain compound 64 (10.7 mg, 74.5% yield) as a yellow solid. [ka]

[0262] The physical properties of compound 64 prepared in Example 64 are as follows: 1H NMR (600 MHz, CDCl3) δ 9.89 (d, J = 7.6 Hz, 1H), 8.43 (s, 1H), 7.86 (d, J = 7.1 Hz, 2H), 7.57 (m, 1H), 7.51 (t, J = 7.6 Hz, 2H), 7.43 (m, 4H), 6.80 (d, J = 8.6 Hz, 2H), 3.42 (q, J = 7.1 Hz, 4H), 2.64 (s, 3H), 1.22 (t, J = 7.1 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 195.8, 185.4, 140.4, 134.5, 131.4, 129.3, 129.2, 128.4, 128.2, 124.9, 122.8, 120.4, 112.3, 111.4, 44.6, 26.3, 12.7; LRMS (ESI) m / z calcd for C 27 H 27 N2O2[M+H] + : 411.20; found: 411.3622.

[0263] Example 65: Preparation of Compound 65 In Example 61, 4-(dipropylamino)phenylboronic acid (11.9 mg, 0.05 mmol), tetrakis(triphenylphosphine)palladium (19.0 mg, 0.3 mol%) and sodium carbonate (17.0 mg, 0.16 mmol) were added to a solution containing IH-B (5.3 mg, 0.01 mmol) and a 1:1 mixture of DMF and water, and the mixture was stirred at 100° C. for 3 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:2-ethyl acetate 33%), and the same procedure as in Example 61 was used to obtain compound 65 (6.1 mg, 92.8% yield) as a yellow solid. [ka]

[0264] The physical properties of compound 65 prepared in Example 65 are as follows: 1 H NMR (600 MHz, CDCl3) δ 9.88 (d, J = 7.4 Hz, 1H), 8.43 (s, 1H), 7.85 (d, J = 7.1 Hz, 2H), 7.57 (dd, J = 10.4, 4.2 Hz, 1H), 7.50 (t, J = 7.6 Hz, 2H), 7.44 (dd, J = 7.3, 1.8 Hz, 1H), 7.41 (t, J = 4.3 Hz, 3H), 6.75 (d, J = 8.8 Hz, 2H), 3.30 (m, 4H), 2.64 (s, 3H), 1.66 (dd, J = 15.1, 7.5 Hz, 4H), 0.96 (t, J = 7.3Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 195.8, 147.6, 140.4, 131.4, 129.2(2), 128.4, 128.2, 124.9, 122.8, 120.4, 112.2, 111.4, 54.1, 53.0, 51.9, 47.6, 29.8, 26.3, 20.5, 11.6; LRMS (ESI) m / z calcd for C 29 H 31 N2O2[M+H] + : 439.23; found:.439.3939

[0265] Example 66: Preparation of Compound 67 Example 66-1: Preparation of (1-bromoindolizin-3-yl)(phenyl)methanone (IM-B) In the same manner as in Example 46-1, (1-bromoindolizin-3-yl)(phenyl)methanone, which is a compound represented by IM-B, was produced.

[0266] Example 66-2: Preparation of Compound 67 To a solution of IM-B (21.6 mg, 0.07 mmol) in 2:1 DMF and water, 4-pyridylboronic acid (26.5 mg, 0.21 mmol), tetrakis(triphenylphosphine)palladium (25.0 mg, 0.3 mol%) and sodium carbonate (22.8 mg, 0.21 mmol) were added and stirred at 100 °C for 12 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:1-ethyl acetate50%) to give compound 67 (5.1 mg, 23.7% yield) as a yellow solid. [ka]

[0267] The physical properties of the compound 67 prepared are as follows: 1 H NMR (600 MHz, CDCl3) δ 9.98 (d, J = 7.1 Hz, 1H), 7.79 (m, 3H), 7.53 (m, 6H), 7.36 (m, 1H), 7.19 (m, 1H), 6.94 (t, J = 6.8 Hz, 1H), 6.53 (d, J = 4.6 Hz, 1H); 13 C NMR (100 MHz, CDCl3) δ 185.1, 149.6, 140.4, 136.6, 132.2, 132.1, 131.4, 129.5, 129.0, 128.5(2), 126.4, 125.7, 122.1, 117.3, 114.9; LRMS (ESI) m / z calcd for C 20 H 15 NO [M+H] + : 299.11; found: 299.1516.

[0268] Example 67: Preparation of Compound 68 In Example 66, 3-amino-4-methylphenylboronic acid (46.7 mg, 0.30 mmol), tetrakis(triphenylphosphine)palladium (33.0 mg, 0.3 mol%) and sodium carbonate (33.0 mg, 0.3 mmol) were added to a solution containing IM-B (23.2 mg, 0.07 mmol) and a mixture of DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 6 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:2-ethyl acetate 33%), and the same procedure as in Example 66 was repeated to obtain compound 68 (20.4 mg, 81.2% yield) as a yellow solid. [ka]

[0269] The physical properties of the compound 68 prepared are as follows: 1 H NMR (600 MHz, (CD3)2SO) δ 9.92 (d, J = 7.0 Hz, 1H), 8.00 (d, J = 9.0 Hz, 1H), 7.81 (dd, J = 7.9, 0.9 Hz, 2H), 7.62 (t, J = 7.4 Hz, 1H), 7.56 (t, J = 7.6 Hz, 2H), 7.42 (m, 1H), 7.36 (s, 1H), 7.18 (t, J = 6.9 Hz, 1H), 7.00 (d, J = 7.6 Hz, 1H), 6.90 (s, 1H), 6.74 (d, J = 7.6 Hz, 1H), 4.92 (s, 2H), 2.08 (s, 3H); 13 C NMR (100 MHz, (CD3)2SO) δ 183.3, 140.2, 135.4, 131.9, 131.0, 130.4, 128.6, 128.3, 128.0, 125.4, 124.1, 121.1, 118.0, 117.6, 114.7, 54.9, 17.1; LRMS (ESI) m / z calcd for C 22 H 19 NO [M+H]+ : 327.14; found: 327.3095.

[0270] Example 68: Preparation of Compound 69 In Example 66, 4-aminobenzeneboronic acid (25.1 mg, 0.14 mmol), tetrakis(triphenylphosphine)palladium (17.0 mg, 0.3 mol%) and sodium carbonate (15.0 mg, 0.14 mmol) were added to a solution containing IM-B (15.0 mg, 0.04 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 3 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:3-ethyl acetate 25%), and the same procedure as in Example 66 was repeated to obtain compound 69 (13.6 mg, 90.7% yield) as a yellow solid. [ka]

[0271] The physical properties of the compound 69 prepared are as follows: 1 H NMR (600 MHz, CDCl3) δ 10.01 (dt, J = 7.2, 1.0 Hz, 1H), 7.82 (dt, J = 3.4, 1.4 Hz, 3H), 7.53 (m, 1H), 7.47 (m, 2H), 7.37 (s, 1H), 7.34 (m, 2H), 7.21 (ddd, J = 8.8, 6.7, 1.0 Hz, 1H), 6.95 (td, J = 6.9, 1.2 Hz, 1H), 6.76 (m, 2H), 3.74 (s, 2H).; 13 C NMR (100 MHz, CDCl3) δ 184.5, 145.3, 141.1, 136.5, 130.9, 129.1(5), 128.3(2), 125.0(2), 124.7, 122.0, 118.1, 117.9, 115.6, 114.2, 29.8; LRMS (ESI) m / z calcd for C 21 H17 NO [M+H] + : 313.13; found: 313.2500.

[0272] Example 69: Preparation of Compound 70 In Example 66, 4-(diethylamino)phenylboronic acid (30.5 mg, 0.15 mmol), tetrakis(triphenylphosphine)palladium (18.0 mg, 0.3 mol%) and sodium carbonate (17.0 mg, 0.15 mmol) were added to a solution containing IM-B (16.0 mg, 0.05 mmol) and a mixture of DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 2 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:2-ethyl acetate 33%), and the same procedure as in Example 66 was repeated to obtain compound 70 (17.3 mg, 90.3% yield) as a yellow solid. [ka]

[0273] The physical properties of the compound 70 prepared are as follows: 1 H NMR (600 MHz, CDCl3) δ 10.03 (dt, J = 7.0, 1.0 Hz, 1H), 7.87 (dt, J = 8.9, 1.2 Hz, 1H), 7.84 (m, 2H), 7.54 (m, 1H), 7.49 (m, 2H), 7.41 (m, 2H), 7.39 (s, 1H), 7.21 (ddd, J = 8.9, 6.7, 1.1 Hz, 1H), 6.96 (td, J = 6.9, 1.3 Hz, 1H), 6.77 (m, 2H), 3.40 (q, J = 7.1 Hz, 4H), 1.20 (t, J = 7.1 Hz, 6H); 13C NMR (100 MHz, CDCl3) δ 184.3, 146.7, 141.2, 136.5, 130.8, 129.1(2), 128.2, 124.9, 124.5, 122.0, 121.5, 118.5, 118.0, 114.1, 112.2, 44.5, 12.7; LRMS (ESI) m / z calcd for C 25 H 25 NO [M+H] + : 369.19; found: 369.3269.

[0274] Example 70: Preparation of Compound 71 In Example 66, 4-(dipropylamino)phenylboronic acid (10.0 mg, 0.05 mmol), tetrakis(triphenylphosphine)palladium (16.0 mg, 0.03 mol%) and sodium carbonate (14.0 mg, 0.13 mmol) were added to a solution containing IM-B (13.0 mg, 0.05 mmol) and a mixture of DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 3 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:2-ethyl acetate 33%), and the same procedure as in Example 66 was repeated to obtain compound 71 (10.0 mg, 50.4% yield) as a yellow solid. [ka]

[0275] The physical properties of the compound 71 prepared are as follows: 1H NMR (600 MHz, CDCl3) δ 10.01 (dt, J = 7.1, 1.1 Hz, 1Hz), 7.85 (dt, J = 8.9, 1.2 Hz, 1H), 7.82 (m, 2H), 7.52 (m, 1H), 7.48 (m, 3H), 7.38 (m, 2H), 7.37 (s, 1H), 7.20 (ddd, J = 8.9, 6.7, 1.1 Hz, 1H), 6.94 (td, J = 6.9, 1.3 Hz, 1H), 6.71 (m, 1H), 3.26 (m, 4H), 1.63 (dd, J = 15.2, 7.5 Hz, 4H), 0.94 (t, J = 7.4 Hz, 6H); 13 C NMR (100 MHz, CDCl3) δ 184.3, 147.1, 141.2, 136.5, 130.8, 129.1, 129.0, 128.2, 124.9, 124.5, 122.0, 121.3, 118.5, 118.0, 114.1, 112.0, 53.0, 20.5, 11.6; LRMS (ESI) m / z calcd for C 27 H 29 N2O [M+H] + : 397.22; found: 397.3389.

[0276] Example 71: Production of Compound 73 Example 71-1: Production of 1-(1-bromo-7-(trifluoromethyl)indolizin-3-yl)ethanone (IB-B)

change

[0277] IB-E: The product was synthesized according to the reaction formula 1-13. Specifically, 4(trifluoromethyl)pyridine (695μL, 6.00mmol) and chloroacetone (501μL, 6.30mmol) were added to DMF (10.0mL) at 100℃ overnight, and then ethyl acrylate (320μL, 3mmol), copper(II) acetate monohydrate (1.79g, 9.00mmol) and sodium acetate (1476.5mg, 18mmol) were added and stirred at 100℃ for 16 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water, and the organic material was extracted with DCM three times. The extracted organic materials were combined, dried over anhydrous Na2SO4, and then concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1–15% hexane with EtOAc) to give compound IB-E (659.5 mg, 2.2 mmol, 73.4% yield) as a yellow solid.

[0278] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.96 (d, J = 7.2 Hz, 1H), 8.66 (t, J = 1.2Hz, 1H), 8.06 (s, 1H), 7.15 (dd, J = 2 Hz, 1H), 4.43 (q, J = 7.2 Hz, 2H), 2.63(s, 3H), 1.45 (t, J = 7.0 Hz, 3H); 13 C NMR(400 MHz, CDCl3) δ 188.0, 163.1, 136.7, 129.1, 128.3, 128.0, 127.6, 127.3, 126.9, 126.0, 124.2, 123.4, 121.5, 118.8, 116.9, 116.8, 110.5, 110.4, 108.1, 60.6, 27.5, 14.5; LRMS (ESI) m / z calcd for C 14 H 12 F3NO3[M+Na] +: 299.1, found : 300.1.

[0279] IB-B : KOH (5386 mg, 96.00 mmol) was added to IB-E (0.66 g, 2.20 mmol) in methanol (10 mL) and stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IB-A as a brown solid.

[0280] The obtained compound IB-A was used immediately in the next step without further purification. Sodium bicarbonate (554 mg, 6.60 mmol) was added to IB-A in DMF (10.0 mL), and NBS (587 mg, 3.30 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IB-B (588 mg, 1.92 mmol, 100% yield) as a yellow solid.

[0281] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3) δ 9.88 (d, J = 7.2 Hz, 1H), 7.85 (s, 1H), 7.60 (s, 1H), 7.02 (d, J = 7.6 Hz, 1H), 2.59 (s, 1H); 13 C NMR(100 MHz, CDCl3) δ 204.4, 186.9, 133.6, 128.7, 124.9, 123.5, 121.7, 115.2, 109.7, 92.0, 27.5.

[0282] Example 71-2: Preparation of Compound 73 To a solution of IB-B (74.6 mg, 0.24 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (103 mg, 0.97 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (49.0 mg, 0.46 mmol) were added and stirred at 100 °C for 8 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 73 (75.9 mg, 0.2 mmol, 85% yield) as a yellow solid. [ka]

[0283] The physical properties of the compound 73 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.95 (d, J = 7.2 Hz, 1H), 8.03 (s, 1H), 7.75 (d, J = 8.4 Hz, 2H), 7.71 (s, 1H), 7.67 (d, J = 8.0 Hz, 2H), 7.03 (dd, J = 7.4 Hz, 2.0 Hz, 1H), 2.65 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 187.6, 137.4, 133.0, 129.2, 129.0, 128.1, 126.1, 125.7, 125.5, 124.6, 123.8, 123.1, 122.8, 121.9, 118.2, 115.1, 109.7, 27.8; LRMS (ESI) m / z calcd for C 18 H 12 F6NO [M+H] + : 372.07; found: 372.05.

[0284] Example 72: Preparation of Compound 74 In Example 71-2, 4-acetylphenylboronic acid (144 mg, 0.88 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (93.0 mg, 0.88 mmol) were added to a solution containing IB-B (52.4 mg, 0.22 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 17 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (56.4 mg, 0.16 mmol, 74.2% yield) was produced in the same manner as in Example 71. [ka]

[0285] The physical properties of the compound 74 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.91 (d, J = 7.2 Hz, 1H), 8.06 (d, J = 8.4 Hz, 2H), 8.01 (d, J = 8.0 Hz, 1H), 7.72 (s, 1H), 7.67 (d, J = 8.8 Hz, 1H), 7.63 (d, J = 8.0 Hz, 1H), 7.01 (d, J = 7.2 Hz, 1H), 2.63 (s, 3H), 2.61 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.4, 187.9, 144.4, 138.8, 136.7, 135.8, 133.3, 129.5, 128.0, 127.6, 124.9, 124.1, 123.4, 122.1, 118.7, 115.5, 109.9, 28.1, 27.1; LRMS (ESI) m / z calcd for C 19 H 15 F3NO2[M+H] + found: 346.10.

[0286] Example 73: Preparation of Compound 75 In Example 71-2, an indolizine derivative compound (79.8 mg, 0.26 mmol, 100% yield) was produced in the same manner as in Example 71, except that phenylboronic acid (117 mg, 0.96 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (102 mg, 0.96 mmol) were added to a solution containing IB-B (73.8 mg, 0.24 mmol) and mixed with DMF and water in a 2:1 ratio. [ka]

[0287] The physical properties of the compound 75 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.94 (d, J = 7.6 Hz, 1H), 8.07 (s, 1H), 7.86 (d, J = 8.8 Hz, 2H), 7.73 (d, J = 8.4 Hz, 1H), 7.66 (d, J = 8.0 Hz, 1H), 7.57 (s, 1H), 7.07 (dd, J = 7.2 Hz, 2.0 Hz, 1H), 7.01 (d, J = 8.8 Hz, 1H), 3.90 (s, 3H); 13 C NMR(100 MHz, CDCl3) δ 184.2, 162.6, 137.5, 133.3, 132.1, 131.2, 129.2, 128.1, 126.1, 126.0, 125.8, 125.1, 123.7, 118.2, 113.7, 109.5, 55.6. HRMS (ESI) m / z calcd for C 17 H 13 F3NO [M+H] + : 304.0949; found: 304.0944.

[0288] Example 74: Preparation of Compound 76 In Example 71-2, an indolizine derivative compound (547.2 mg, 0.14 mmol, 64% yield) was produced in the same manner as in Example 71, except that 4-methoxyphenylboronic acid (133 mg, 0.87 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (92.7 mg, 0.87 mmol) were added to a solution containing IB-B (52.1 mg, 0.22 mmol) and mixed with DMF and water in a 2:1 ratio. [ka]

[0289] The physical properties of the compound 76 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.89 (d, J = 7.2 Hz, 1H), 7.99 (s, 1H), 7.60 (s, 1H), 7.45 (d, J = 8.8 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 6.96 (dd, J = 7.4 Hz, 1.6 Hz, 1H), 3.87 (s, 3H), 2.62 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 187.4, 158.8, 132.8, 129.1, 128.8, 126.0, 125.0, 124.8, 124.6, 123.3, 122.7, 122.1, 119.8, 115.5, 114.5, 109.2, 55.5, 27.7; LRMS (ESI) m / z calcd for C 18 H 15 F3NO2[M+H] + : 334.10; found: 334.15.

[0290] Example 75: Preparation of Compound 77 In Example 71-2, an indolizine derivative compound (85.3 mg, 0.25 mmol, 100% yield) was produced in the same manner as in Example 71, except that 4-(dimethylamino)phenylboronic acid (167 mg, 1.01 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (108 mg, 1.01 mmol) were added to a solution containing IB-B (77.8 mg, 0.25 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 12 hours. [ka]

[0291] The physical properties of the compound 77 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.88 (d, J = 8.0 Hz, 1H), 8.03 (s, 1H), 7.57 (s, 1H), 7.41 (d, J = 8.8 Hz, 2H), 6.94 (dd, J = 7.6 Hz, 2.0 Hz, 1H), 6.83 (d, J = 8.8 Hz, 2H), 3.01 (s, 6H), 2.62 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 186.9, 149.3, 132.4, 128.3, 124.5, 124.1, 123.8, 122.9, 121.9, 121.8, 121.1, 121.0, 120.1, 115.4, 112.5, 108.6, 40.2, 27.3; LRMS (ESI) m / z calcd for C 19 H 18 F3N2O [M+H] + : 347.13; found: 347.15.

[0292] Example 76: Preparation of Compound 78 Example 76-1: Preparation of 1,1'-(1-bromoindolizine-3,7-diyl)diethanone (IG-B) [ka]

[0293] IG-E : The product was synthesized according to the reaction scheme 1-14. Specifically, 4-acetylpyridine (158.1μL, 1.431mmol) and 2-chloroacetone (120.7μL, 1.5mmol) were added to DMF (12.0mL) and stirred at 80℃ for 4 hours, and then ethyl acrylate (77.5μL, 0.715mmol), copper(II) acetate monohydrate (856.5mg, 4.29mmol) and sodium acetate (469.2mg, 5.72mmol) were added and stirred at 100℃ for 5 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water and the organic material was extracted with DCM three times. The extracted organic materials were combined, dried over anhydrous Na2SO4, and then concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate 40%) to give compound IG-E (166.7 mg, 85.3% yield) as a yellow solid.

[0294] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.85(d, J = 6.8 Hz, 1H), 8.80(s, 1H), 7.44(d, J = 7.4 Hz, 1H), 4.39(q, J = 14.2 Hz, 2H), 2.62(s, 3H), 2.58(s, 3H), 1.43(t, J = 7.6Hz, 3H); 13C NMR(100 MHz, CDCl3), δ 185.4, 159.1, 140.2, 134.6, 131.8, 131.6, 129.5, 129.2, 128.5, 128.3, 126.4, 125.4, 123.8, 121.8, 121.6, 119.9, 114.8, 111.7, 55.7, 26.7 ; LRMS (ESI) m / z calcd for C 15 H 15 NO4[M+Na] + : 273.3, found : 274.1.

[0295] IG-B IG-E (166.7 mg, 0.610 mmol) in methanol (5 mL) was added with KOH (1.37 g, 24.4 mmol) and stirred at room temperature overnight. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IG-A as a brown solid.

[0296] The obtained compound IG-A was used immediately in the next step without further purification. Sodium bicarbonate (51.2 mg, 1.83 mmol) was added to IG-A in DMF (10.0 mL), and NBS (108.5 mg, 0.64 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to obtain compound IG-B (135.5 mg, 79.3% yield) as a yellow solid.

[0297] The results of the NMR analysis are as follows: 1H NMR(400 MHz, CDCl3), δ 9.65(d, J = 7.4 Hz, 1H), 8.00(s, 1H),7.49(s, 1H), 7.32(d, 7.4Hz), 2.63(s, 3H), 2.53(s, 3H); 13 LRMS (ESI) m / z calcd for C 12 H 10 BrNO2[M+Na] + : 280.1, found : 280.0.

[0298] Example 76-2: Preparation of Compound 78 To a solution of IG-B (25.0 mg, 0.089 mmol) in 10:1 DMF and water, 4-trifluorophenylboronic acid (50.71 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium (20.58 mg, 0.018 mmol) and sodium carbonate (47.13 mg, 0.45 mmol) were added and stirred at 100 °C for 8 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate40%) to give compound 78 (29.9 mg, 97.2% yield) as a yellow solid. [ka]

[0299] The physical properties of the compound 78 prepared are as follows: 1H NMR (400 MHz, CDCl3) δ 9.86 (d, J = 7.6 Hz, 1H), 8.36 (s, 1H), 7.77 (d, J = 8.4 Hz, 2H), 7.70 (d. J = 12.0 Hz, 3H), 7.42(dd, J = 8.0 Hz, 2.0 Hz, 1H), 2.66 (s, 3H), 2.64 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.5, 187.9, 156.9, 137.8, 134.0, 132.1, 129.5, 129.1, 128.4, 126.3 (2), 125.7, 124.4, 123.1, 123.0, 119.8, 119.1, 112.1, 28.1, 26.7; LRMS (ESI) m / z calcd for C 19 H 15 F3NO2[M+H] + found: 346.10.

[0300] Example 77: Preparation of Compound 79 In Example 76-2, an indolizine derivative compound (27.6 mg, 97.2% yield) was produced in the same manner as in Example 76, except that 4-acetylphenylboronic acid (43.78 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium (20.58 mg, 0.018 mmol) and sodium carbonate (47.13 mg, 0.45 mmol) were added to a solution containing IG-B (25.0 mg, 0.089 mmol) and mixed with DMF and water in a ratio of 10:1. [ka]

[0301] The physical properties of the compound 79 prepared are as follows: 1H NMR (400 MHz, CDCl3) δ 9.86 (d, J = 7.4 Hz, 1H), 8.39 (s, 1H), 8.10 (dd, J = 6.6 Hz, 1.6 Hz, 2H), 7.70 (d, J = 4.0 Hz, 2H), 7.69 (s, 1H), 7.42 (dd, J = 7.2 Hz, 2.0 Hz, 1H), 2.67 (s, 3H), 2.66 (s, 3H), 2.64 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.5, 195.5, 187.9, 139.0, 135.7, 134.1, 132.1, 129.4, 128.5, 128.1, 124.4, 123.1, 120.1, 119.3, 112.1, 28.1, 27.1, 26.7; LRMS (ESI) m / z calcd for C 20 H 18 NO3[M+H] + : 320.12; found: 320.10.

[0302] Example 78: Preparation of Compound 80 In Example 76-2, an indolizine derivative compound (23.5 mg, 95.4% yield) was produced in the same manner as in Example 76, except that phenylboronic acid (32.56 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium (20.58 mg, 0.018 mmol) and sodium carbonate (47.13 mg, 0.45 mmol) were added to a solution containing IG-B (25.0 mg, 0.089 mmol) and mixed with DMF and water in a ratio of 10:1. [ka]

[0303] The physical properties of the compound 80 prepared are as follows: 1H NMR (400 MHz, CDCl3) δ 9.82 (d, J = 7.4 Hz, 1H), 8.37 (s, 1H), 7.64 (s, 1H), 7.59 (dd, J = 6.8 Hz, 1.6 Hz, 2H), 7.51 (dt, J = 7.2 Hz, 2.4 Hz 2H), 7.40 (t, J = 7.2 Hz, 2H), 2.64 (s, 3H), 2.61(s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 187.8, 134.1, 133.9, 131.6, 129.3, 128.3, 128.2, 127.4, 124.1, 122.9, 121.7, 119.8, 111.7, 28.1, 26.7; HRMS (ESI) m / z calcd for C 18 H 16 NO2[M+H] + : 278.1181; found: 278.1176.

[0304] Example 79: Preparation of Compound 81 In Example 76-2, an indolizine derivative compound (26.5 mg, 96.9% yield) was produced in the same manner as in Example 76, except that 4-methoxyphenylboronic acid (40.57 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium (20.58 mg, 0.018 mmol) and sodium carbonate (47.13 mg, 0.45 mmol) were added to a solution containing IG-B (25.0 mg, 0.089 mmol) and mixed with DMF and water in a ratio of 10:1. [ka]

[0305] The physical properties of the compound 81 prepared are as follows: 1H NMR (400 MHz, CDCl3) δ 9.78 (d, J = 7.4 Hz, 1H), 8.31 (s, 1H), 7.57 (s, 1H), 7.49 (dd, J = 7.4 Hz, 1.6Hz, 2H), 7.35 (dd, J = 7.4 Hz, 1.6 Hz, 1H), 7.04 (d, J = 8.8 Hz, 2H), 3.88 (s, 3H), 2.62 (s, 3H), 2.60 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.6, 187.7, 159.1, 133.8, 131.3, 129.4, 128.1, 126.5, 124.0, 122.6, 121.6, 119.9, 114.8, 111.5, 55.7, 28.0, 26.6; LRMS (ESI) m / z calcd for C 19 H 18 NO3[M+H] + : 308.12; found: 308.10.

[0306] Example 80: Preparation of Compound 82 In Example 76-2, an indolizine derivative compound (26.9 mg, 94.8% yield) was produced in the same manner as in Example 76, except that 4-(dimethylamino)phenylboronic acid (44.06 mg, 0.27 mmol), tetrakis(triphenylphosphine)palladium (20.58 mg, 0.018 mmol) and sodium carbonate (47.13 mg, 0.45 mmol) were added to a solution containing IG-B (25.0 mg, 0.089 mmol) and mixed with DMF and water in a ratio of 10:1. [ka]

[0307] The physical properties of the compound 82 prepared are as follows: 1H NMR (400 MHz, CDCl3) δ 9.78 (d, J = 7.2 Hz, 1H), 8.36 (s, 1H), 7.56 (s, 1H), 7.47 (dd, J = 9.2 Hz, 2.4 Hz, 2H), 7.36 (dd, J = 7.8 Hz, 2.4 Hz, 1H), 6.87 (d, J = 8.8 Hz, 2H), 3.03 (s, 6H), 2.64 (s, 3H), 2.60 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 195.7, 187.7, 149.9, 133.8, 131.0, 129.1, 128.0, 124.0, 122.4, 122.3, 122.0, 121.6(2), 120.3, 113.2, 111.4, 111.2, 40.9, 28.1, 26.6; LRMS (ESI) m / z calcd for C 20 H 21 N2O2[M+H] + : 321.15; found: 321.15.

[0308] Example 81: Production of Compound 83 Example 81-1: Production of 1-(1-bromoindolizin-3-yl)ethanone (IL-B)

change

[0309] IL-E: The product was synthesized according to the above reaction scheme 1-15. Specifically, pyridine (564μL, 7.00mmol) and chloroacetone (585μL, 7.35mmol) were added to DMF (15.0mL) and stirred at 100℃ overnight, and then ethyl acrylate (373μL, 3.50mmol), copper(II) acetate monohydrate (2.09g, 10.5mmol) and sodium acetate (1.72g, 21.0mmol) were added and stirred at 100℃ for 16 hours. After completion of the reaction, the copper acetate was removed by filtration through a Celite pad and the filtrate was concentrated under vacuum. The crude product was washed with water and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and then concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (1–15% hexane with EtOAc) to give compound IL-E (633 mg, 2.73 mmol, 85.0% yield) as a yellow solid.

[0310] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.88 (d, J = 6.4 Hz, 1H), 8.34(d, J = 5.0 Hz, 1H), 7.99(s, 1H), 7.38(q, J = 9.3 Hz, 1H), 6.95(t, J = 7.0 Hz, 1H), 4.39(q, J = 7.1 Hz, 2H), 2.60(s, 3H), 1.43(t, J = 7.2 Hz, 3H); 13 C NMR(100 MHz, CDCl3) δ 187.6, 164.0, 139.2, 129.1, 127.2, 126.2, 122.7, 119.4, 115.2, 105.8, 60.3, 27.6, 14.9; LRMS (ESI) m / z calcd for C 13 H 13 NO3[M+Na] + : 231.1, found : 232.1.

[0311] IL-B IL-E (633 mg, 2.73 mmol) in methanol (20 mL) was added with KOH (6.14 g, 109 mmol) and stirred at room temperature for 4 hours. The reaction mixture was acidified with 6N HCl, and the resulting solid was collected by filtration, washed with water, and dried in a drying oven to obtain compound IL-A as a white solid.

[0312] The obtained compound IL-A was used immediately in the next step without further purification. Sodium bicarbonate (688 mg, 8.19 mmol) was added to IL-A in DMF (10.0 mL), and NBS (2.18 g, 12.3 mmol) was added in portions at 0° C. The reaction mixture was stirred at room temperature for 12 hours, and the resulting crude product was washed with water, and the organic material was extracted three times with DCM. The extracted organic materials were combined, dried over anhydrous Na2SO4, and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:8-ethyl acetate12%) to obtain compound IL-B (477 mg, 2.0 mmol, 73.4% yield) as a yellow solid.

[0313] The results of the NMR analysis are as follows: 1 H NMR(400 MHz, CDCl3), δ 9.83 (d, J = 6.8 Hz, 1H), 7.56 (d, J = 9.2 Hz, 1H), 7.51 (s, 1H), 7.22 (q, J = 7.8 Hz, 1H), 6.91 (t, J = 6.4 Hz, 1H), 2.54 (s, 3H); 13 LRMS (ESI) m / z calcd for C 10 H8BrNO[M+Na] + : 237.0, found :238.0.

[0314] Example 81-2: Preparation of Compound 83 To a solution of IL-B (21.7 mg, 0.09 mmol) in 2:1 DMF and water, 4-trifluorophenylboronic acid (69.0 mg, 0.36 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (39.0 mg, 0.36 mmol) were added and stirred at 100 °C for 10 h. After completion of the reaction, it was monitored by TLC, washed with water and the organic material was extracted with DCM three times. The extracted organic material was combined, dried over anhydrous Na2SO4 and concentrated. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:4-ethyl acetate25%) to give compound 83 (24.4 mg, 0.08 mmol, 89.3% yield) as a yellow solid. [ka]

[0315] The physical properties of the compound 83 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.93 (d, J = 7.6 Hz, 1H), 7.82 (d, J = 9.2 Hz, 2H), 7.69 (d, J = 4.4 Hz, 2H), 7.65 (s, 1H), 7.49 (d, J = 8.6 Hz, 1H), 7.24 (d, J = 10.0 Hz, 1H), 6.95 (dt, J = 6.9 Hz, 1.2 Hz, 1H), 2.62 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 186.8, 138.4, 135.7, 129.0, 128.1, 127.8, 125.8, 125.8, 125.6, 125.1, 122.8, 122.6, 117.1, 115.5(2), 114.4, 27.5; LRMS (ESI) m / z calcd for C 17 H 13 F3NO [M+H]+ : 304.09; found: 304.05.

[0316] Example 82: Preparation of Compound 84 In Example 81-2, 4-acetylphenylboronic acid (71.0 mg, 0.43 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (46.0 mg, 0.43 mmol) were added to a solution containing IL-B (25.8 mg, 0.10 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 12 hours. The concentrated organic phase was purified by silica-gel flash column chromatography (EA:Hexane=1:5-ethyl acetate20%), but an indolizine derivative compound (19.0 mg, 0.06 mmol, 63.4% yield) was produced in the same manner as in Example 81. [ka]

[0317] The physical properties of the compound 84 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.91 (d, J = 6.8 Hz, 1H), 8.04 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.8 Hz, 1H), 7.68 (s, 1H), 7.66 (d, J = 3.6 Hz, 2H), 7.23 (dt, J = 7.8 Hz, 1.2 Hz, 1H), 6.93 (dt, J = 6.9 Hz, 1.2 Hz, 1H), 2.63 (s, 3H), 2.61 (s, 3H); 13 C NMR (100 MHz, CDCl3) δ 197.5, 186.9, 139.9, 135.7, 134.9, 129.1, 127.6, 127.5, 125.3, 122.9, 122.8, 117.5, 115.7, 114.5, 27.7, 27.0; LRMS (ESI) m / z calcd for C 18 H16 NO2[M+H] + : 278.11; found: 278.14.

[0318] Example 83: Preparation of Compound 85 In Example 81-2, an indolizine derivative compound (66.8 mg, 0.28 mmol, 100% yield) was produced in the same manner as in Example 81, except that phenylboronic acid (111 mg, 0.91 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (97.0 mg, 0.91 mmol) were added to a solution containing IL-B (54.4 mg, 0.23 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 9 hours. [ka]

[0319] The physical properties of the compound 85 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.91 (d, J = 7.2 Hz, 1H), 7.83 (d, J = 8.8 Hz, 1H), 7.61 (s, 1H), 7.58 (d, J = 7.2 Hz, 2H), 7.46 (t, J = 7.6 Hz, 2H), 7.32 (t, J = 7.4 Hz, 1H), 7.17 (dt, J = 4.4 Hz, 1.2 Hz, 1H), 6.90 (t, J = 6.8 Hz, 1H), 2.60 (s, 3H); 13 LRMS (ESI) m / z calcd for C 16 H 14 NO [M+H] + found: 236.10.

[0320] Example 84: Preparation of Compound 86 In Example 81-2, an indolizine derivative compound (13.3 mg, 0.05 mmol, 62.6% yield) was produced in the same manner as in Example 81, except that 4-methoxyphenylboronic acid (52.0 mg, 0.34 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (36.0 mg, 0.34 mmol) were added to a solution containing IL-B (20.3 mg, 0.08 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 13 hours. [ka]

[0321] The physical properties of the compound 86 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.90 (d, J = 6.8 Hz, 1H), 7.77 (d, J = 6.8 Hz, 1H), 7.55 (s, 1H), 7.49 (d, J = 8.8 Hz, 2H), 7.16 (dt, J = 7.7 Hz, 1.2 Hz, 1H), 7.01 (t, J = 6.8 Hz, 2H), 6.89 (dt, J = 6.9 Hz, 1.2 Hz, 1H), 3.87 (s, 3H), 2.60 (s, 3H); 13 LRMS (ESI) m / z calcd for C 17 H 16 NO2[M+H] + : 266.11; found: 266.10.

[0322] Example 85: Preparation of Compound 87 In Example 81-2, an indolizine derivative compound (12.5 mg, 0.04 mmol, 40.8% yield) was produced in the same manner as in Example 81, except that 4-(dimethylamino)phenylboronic acid (76.0 mg, 0.46 mmol), tetrakis(triphenylphosphine)palladium (231 mg, 20.0 mol%) and sodium carbonate (49.0 mg, 0.46 mmol) were added to a solution containing IL-B (27.5 mg, 0.11 mmol) and mixed with DMF and water in a ratio of 2:1, and the mixture was stirred at 100° C. for 11 hours. [ka]

[0323] The physical properties of the compound 87 prepared are as follows: 1 H NMR (400 MHz, CDCl3) δ 9.89 (d, J = 6.4 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.53 (s, 1H), 7.46 (d, J = 7.2 Hz, 2H), 7.13 (t, J = 7.8 Hz, 1H), 6.84 (d, J = 6.8 Hz, 3H), 3.00 (s, 6H), 2.59 (s, 3H); 13 LRMS (ESI) m / z calcd for C 18 H 19 NO [M+H] + : 279.14; found: 279.15.

[0324] Experimental Method Cell culture and reagents Human single cell line THP-1 WT and STING KO cell lines were purchased from Invivogen. Cells were cultured in a culture medium containing 1XRPMI1640 containing 10% fetal bovine serum (FBS, Hyclone), 2.05 mM L-glutamine (hyclone) and 1% penicillin (corning) at 37°C in a humidified incubator with 5% CO2. Luciferase reporter assay To confirm the immunoreactivity, THP-1 cells were placed in 384-well plates (Grenier) and treated with individual compounds and cGAMP (1 μg / ml), and ISRE activity was analyzed after 24 hours. To confirm the luciferase reporter gene signal, the cell culture supernatant was used for the QUANTI-Luc assay (Invivogen). The fluorescent signal was measured using a TECAN microplate reader SPARK, and the results were normalized using a DMSO control.

[0325] Cell viability assay Cells were analyzed using CellTiter Clo (CTG, Promega). Absorbance was measured using a TECAN microplate reader SPARK. Results were normalized using a DMSO control.

[0326] ELISA analysis Cytokine levels were determined by ELISA analysis. THP-1 cells were placed in 96-well U-bottom plates and treated with compounds and cGAMP (1 μg / ml) for 24 h before testing. After incubation, cell supernatants were collected and human IFNβ and IP-10 were determined by ELISA analysis.

[0327] Gene expression analysis by real-time quantitative PCR For gene expression confirmation, THP-1 cells were placed in a 24-well plate (SPL) and treated with the compounds of the present invention and cGAMP (1 μg / ml) for 6 hours. After incubation, the cells were cultured using NucleoSpin RNA Plus (MN) for RNA isolation. The expression levels of IFNB, CXCL10, IFIT3, ISG15, IRF7 and OAS1 mRNA were measured by real-time qPCR (CFX96 Real-Time PCR Detection System, Bio-Rad) using IQ SYBR Green Supermix (Bio-Rad). GAPDH was used as a housekeeping gene to normalize the cytokine mRNA levels.

[0328] Western blot analysis Cells were incubated and lysed in RIPA buffer containing protease and phosphate inhibitor cocktail (TERMO) and Benzonase Nuclease (SIGMA). After centrifugation, the supernatant was obtained, and protein content was measured using a BCA protein assay kit (HERMO). Cell lysates were analyzed by SDS-PAGE using acrylamide gels. After SDS-PAGE, proteins were transferred to PVDF membranes, blocked with 5% BSA, and washed with TBST. The membranes were incubated overnight at 4°C with the respective primary antibodies (anti-STING, anti-pSTING, anti-TBK, anti-pTBK, anti-IRF3, anti-pIRF3, anti-STAT1, anti-pSTAT1, and anti-actin). After washing with TBST, HRP-conjugated secondary antibodies were treated for 1 h at room temperature. The membranes were washed with TBST and treated with ECL solution (THERMO). Chemifluorescence images were taken with a ChemiDOC (Bio-Rad).

[0329] Anticancer activity of Compound 42 in vivo Eight-week-old female BALB / c mice (DBL) were used in the experiment. The right flank was inoculated with 0.5 × 10 6 4T1 tumor cells were inoculated subcutaneously. After tumor implantation, the tumor size was approximately 100 mm 3 When the tumor volume reached 100 μg / kg, mice were randomized into treatment groups, each consisting of N=4 (vehicle N=1), and then administered with compound. Five days after tumor cell injection, compounds or vehicle were administered intravenously (20 mg / kg) or vehicle (5% DMSO, 5% Tween 80 in PBS). 2'3'-cGAMP (Invivogen) was injected intratumorally (2 μg in PBS). Compound 42 was injected once daily, and cGAMP was injected once every 4 days. Tumor and body weight measurements were performed using digital calipers and a weighing scale, respectively. Tumor volume was estimated using the following formula 1:

number

[0330] PK profiles of Compound 42 after IV and PO administrations to BALB / c mice The pharmacokinetics and oral bioavailability of compound 42 were investigated in mice by single intravenous (IV) injection and oral administration (PO). As shown in Figure 8 below, blood samples were taken at six time points (4 hours, 8 hours, 12 hours, 16 hours, 20 hours, and 24 hours) for each administration route, and the amount of compound in the blood was analyzed by LC / MS.

[0331] Experimental results and analysis Results of indolizine derivatives discovery When 86 indolizine derivatives were co-administered with a very small dose of cGAMP (1ug / ml), the immune response in THP-1 cells was confirmed by ISRE reporter assay and ISRE reporter gene assay, and the cytotoxicity due to the co-administration was also confirmed (Table 1). All results were normalized and compared with the results of the reporter assay in which only cGAMP was administered. As a result, the indolizine derivative compound 42, which had the highest co-administration efficacy and was non-toxic, was used below. [Table 1-1] [Table 1-2] [Table 1-3]

[0332] Confirmation of STING dependency As can be seen in Figure 1, the efficacy of combined administration was effectively increased in the WT cell line, whereas no effect was observed at all in the STING KO cell line, and this effect was confirmed to be concentration-dependent.

[0333] Thus, compound 42 was demonstrated to highly effectively increase cGAMP-induced ISRE signal in a concentration-dependent and STING-dependent manner.

[0334] On the other hand, as can be seen from FIG. 2, it was confirmed that the combined administration of compound 42 and cGAMP did not cause toxicity to cells.

[0335] Confirmation of cytokine expression by combined administration As can be seen from FIG. 3, the amount of parent immunoreactive cytokines secreted by cGAMP, such as IFN-β and IP-10, was measured using ELISA as well as ISRE reporter gene assay. The results showed that the combined administration of Compound 42 and cGAMP increased cytokine secretion more effectively in a concentration-dependent manner than the administration of cGAMP alone, and that there was no immunoreactivity when Compound 42 was administered alone.

[0336] Confirmation of type I IFN signaling-related gene expression As can be seen from FIG. 4, the expression of various interferon stimulated genes (ISGs), including IFNB induced by cGAMP, such as IP-10, ISG15, IRF7, IFIT3, and OAS1, was significantly increased by treatment with Compound 42, confirming that Compound 42 effectively promotes type I IFN immune responses induced by cGAMP.

[0337] Confirmation of TBK, IRF3, and STAT1 activity (Western blot) As can be seen from FIG. 5, compound 42 demonstrated a mechanism of efficacy of combined administration by increasing phosphorylation of IRF3 and STAT1, which are downstream signal transduction pathways of STING and TBK induced by cGAMP.

[0338] STING pathway-activating therapeutic agents and comparison of activity As can be seen in Figure 6, the degree of STING-dependent immune response activation of compound 42 was compared with that of ENPP inhibitor MV658 compound, which is known as a STING pathway activating therapeutic substance, demonstrating that compound 42 showed superior activity.

[0339] Confirmation of in vivo anticancer activity As can be seen from FIG. 7, when compound 42 was administered in combination with cGAMP, the tumor volume was more effectively reduced than when cGAMP was administered alone, demonstrating the anticancer activity in vivo.

[0340] Checking PK profile As can be seen from FIG. 8 and Tables 2 and 3 below, it has been demonstrated that IV and PO administration is possible. Specifically, the half-life of IV 5mpk administration was approximately 7.76 hours, and C max was 2747ng / ml, AUC ∞ The mean volume of distribution at steady state (Vss) was 10.15 L / kg and the mean blood clearance was 22.66 mL / min / kg after IV administration. On the other hand, after PO administration of 20 mpk, the half-life was 11.6 hours and the C max was 224ng / ml, AUC ∞ The oral bioavailability was 18%, indicating the feasibility of intravenous and oral administration. [Table 2] [Table 3]

[0341] conclusion Based on the above results, it was confirmed that the compound of the present invention very effectively increases the Type I IFN-related innate immune response of STING induced by cGAMP, and that the compound of the present invention is a very effective candidate for co-administration of drugs to induce innate immune responses by STING activity. In addition, it was confirmed in another experiment that the compound of the present invention alone was not very effective, so it can be expected that there will be fewer side effects. Furthermore, it was confirmed that the compound of the present invention exhibits more effective anti-cancer activity in vivo when co-administered with cGAMP. This result demonstrated the possibility of STING antagonists as co-administration drugs to treat cancer cells that have evaded the immune surveillance system.

[0342] The present invention has been described above with a focus on its preferred embodiments. Those skilled in the art will understand that the present invention can be realized in modified forms without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an explanatory perspective, not a restrictive one. The scope of the present invention is defined in the claims, not the above description, and all differences within the scope of the equivalents thereof should be interpreted as being included in the present invention.

Claims

1. An indolizine derivative compound represented by the following chemical formula 1: STING (stimulator of interferon genes) stimulatory composition containing cyclic-di-nucleotides: 【Chemistry 1】 In the above Chemical Formula 1, R 1 is hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group; a halogen group; a nitrile group; a hydroxy group; 1 -C 6 an alkoxy group of -COY 1 (Here, Y 1 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 2 (Here, Y 2 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 3 Y 4 (Here, Y 3 and Y 4 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 a heteroaryl group of the formula R 2 teeth, 【Chemistry 2】 or a pyridinyl group, R 4 and R 5 are each independently hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 A cycloalkyl group represented by the formula: 5 -C 20 A heterocycloalkyl group represented by the formula: 6 -C 20 an aryl group of C 6 -C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; 1 -C 6 an alkoxy group of -COY 5 (Here, Y 5 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 6 (Here, Y 6 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 7 Y 8 (Here, Y 7 and Y 8 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 a heteroaryl group of the formula R 3 is C 1 -C 8 or a straight or branched chain alkyl group of 【Chemistry 3】 and R 6 is hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 A cycloalkyl group represented by the formula: 5 -C 20 A heterocycloalkyl group represented by the formula: 6 -C 20 an aryl group of C 6 -C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxy group; 1 -C 6 an alkoxy group of -COY 9 (Here, Y 9 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 10 (Here, Y 10 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 11 Y 12 (Here, Y 11 and Y 12 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 (heteroaryl group).

2. The STING (stimulator of interferon genes) stimulant composition according to claim 1, wherein the indolizine derivative compound represented by Chemical Formula 1 is a compound represented by the following Chemical Formula 1-1 or a compound represented by the following Chemical Formula 1-2: 【Chemistry 4】 In the above chemical formula: R 1 is hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group; a halogen group; a nitrile group; a hydroxy group; 1 -C 6 an alkoxy group of -COY 1 (Here, Y 1 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 2 (Here, Y 2 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 3 Y 4 (Here, Y 3 and Y 4 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 a heteroaryl group of the formula R 4 and R 5 are each independently hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 A cycloalkyl group represented by the formula: 5 -C 20 A heterocycloalkyl group represented by the formula: 6 -C 20 an aryl group of C 6 -C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; 1 -C 6 an alkoxy group of -COY 5 (Here, Y 5 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 6 (Here, Y 6 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 7 Y 8 (Here, Y 7 and Y 8 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 a heteroaryl group of the formula R 6 is hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 A cycloalkyl group represented by the formula: 5 -C 20 A heterocycloalkyl group represented by the formula: 6 -C 20 an aryl group of C 6 -C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxy group; 1 -C 6 an alkoxy group of -COY 9 (Here, Y 9 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 10 (Here, Y 10 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 11 Y 12 (Here, Y 11 and Y 12 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 (heteroaryl group).

3. The STING (stimulator of interferon genes) stimulant composition according to claim 1, wherein the indolizine derivative compound represented by Chemical Formula 1 is a compound represented by the following Chemical Formulas 1-3: 【Chemistry 5】 In the above chemical formula: R 1 is hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group; a halogen group; a nitrile group; a hydroxy group; 1 -C 6 an alkoxy group of -COY 1 (Here, Y 1 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 2 (Here, Y 2 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 3 Y 4 (Here, Y 3 and Y 4 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 a heteroaryl group of the formula R 4 and R 5 are each independently hydrogen; 1 -C 8 A straight or branched chain alkyl group of the formula: 1 -C 8 A straight or branched chain alkyl group of the formula: 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 A cycloalkyl group represented by the formula: 5 -C 20 A heterocycloalkyl group represented by the formula: 6 -C 20 an aryl group of C 6 -C 20 a heteroaryl group; a halogen group; a nitrile group; a nitro group; a hydroxyl group; a carboxyl group; 1 -C 6 an alkoxy group of -COY 5 (Here, Y 5 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula: 2 Y 6 (Here, Y 6 is hydrogen, C 1 -C 8 a straight or branched chain alkyl group of 2 -C 8 an alkenyl group of C 2 -C 8 an alkynyl group of C 3 -C 8 or a cycloalkyl group of C 6 -C 20 an aryl group represented by the formula -NY 7 Y 8 (Here, Y 7 and Y 8 are each independently hydrogen, C 1 -C 10 Alkyl groups of C 6 -C 20 or an aryl group of C 4 -C 20 a heteroaryl group of the formula R 3 is C 1 -C 8 is a straight or branched chain alkyl group of the formula:

4. The STING (stimulator of interferon genes) stimulant composition according to claim 1, wherein the indolizine derivative compound represented by Chemical Formula 1 is any one of Compounds 1 to 72 below: 【Chemistry 6-1】 【Chemistry 6-2】 【Chemistry 6-3】 【Chemistry 6-4】 【Chemistry 6-5】 【Chemistry 6-6】 【Chemistry 6-7】 【Chemistry 6-8】 【Chemistry 6-9】 【Chemistry 6-10】 【Chemistry 6-11】 【Chemistry 6-12】

5. The STING (stimulator of interferon genes) stimulant composition according to claim 1, wherein the indolizine derivative compound represented by Chemical Formula 1 is any one of Compounds 73 to 87 below: 【Chemistry 7-1】 【Chemistry 7-2】 【Chemistry 7-3】

6. The STING (stimulator of interferon genes) stimulator composition according to claim 1, wherein the cyclic-di-nucleotide is substituted with fluorine at any one or more of the 2' and 3' positions.

7. The cyclic-di-nucleotide is any one of the following compounds: 【Chemistry 8-1】 【Chemistry 8-2】 【Chemistry 8-3】 【Chemistry 8-4】 【Chemistry 8-5】

8. The composition is for preventing or treating any one of autoimmune diseases, including cancer, solid cancer, non-T cell invasive cancer, cancer with low response to immune checkpoint inhibitors, and infantile-onset STING-associated vasculitis (SAVI), according to claim 1. The STING (stimulator of interferon genes) stimulator composition.

Citation Information

Patent Citations

  • Bicyclic compounds, their compositions and pharmaceutical uses

    JP2018501319A

  • Compositions and methods for activating "stimulator of interferon gene"-dependent signalling

    KR1020180066241A

  • Cyclic dinucleotides as stimulators of interferon gene regulators

    KR1020200058411A

  • Indolizine derivative compound and compound for detecting target material comprising the same

    KR1020220063600A

  • Sting-agonist compound

    WO2020075790A1